sofosbuvir has been researched along with Hepatitis C in 656 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 436 (66.46) | 24.3611 |
| 2020's | 220 (33.54) | 2.80 |
| Authors | Studies |
|---|---|
| Beigelman, L; Deval, J; Dyatkina, N; Fung, A; Hu, Y; Huang, Y; Jekle, A; Jin, Z; Kang, H; Prhavc, M; Serebryany, V; Shaw, K; Smith, DB; Stoycheva, A; Tam, Y; Tan, H; Wan, J; Wang, G; Williams, C; Wu, X; Zhang, Q | 1 |
| Abe, H; Andrei, G; Balzarini, J; Haraguchi, K; Hotta, K; Kaneda, R; Kato, N; Kitagawa, Y; Miyaike, T; Mori, K; Shimada, H; Shuto, S; Snoeck, R; Tanaka, H; Ueda, Y | 1 |
| Chang, J; Ho, W; Li, E; Li, H; Li, S; Liu, B; Lv, Z; Peng, Y; Wang, Q; Wang, Y; Yu, W | 1 |
| Dadej, A; Jelińska, A; Muszalska, I; Sobczak, A; Tomczak, S; Zając, M | 1 |
| Biancone, L; Buggisch, P; Camargo, M; Chuang, WL; Dvory-Sobol, H; Gaggar, A; Hu, TH; Hyland, R; Kirby, BJ; Liu, CH; Lu, S; Mangia, A; Moreno, C; Osinusi, A; Peng, CY; Sise, ME; Su, WW | 1 |
| Chen, R; Li, D; Yuan, X; Zhang, M | 1 |
| Blanquicett, CJ; Cartwright, EJ; Jaglal, M; Johnson, TM; Mirk, A; Raavi, T | 1 |
| El-Shenawy, R; Helmy, NM; Shawky, H | 1 |
| Arteaga, L; Brinkley, S; Brooner, RK; Falade-Nwulia, O; Haselhuhn, T; Herne, K; Katz, S; Latkin, C; Mehta, SH; Moon, J; Sulkowski, MS; Sutcliffe, CG; Ward, KM | 1 |
| Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW | 1 |
| Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M | 1 |
| Bado, P; Djigma, FW; Kabré, MK; Kiendrebeogo, IT; Obiri-Yeboah, D; Ouattara, AK; Simpore, J; Sombie, HK; Sorgho, AP; Tao, I; Yelemkoure, ET; Yonli, AT; Zeba, MTA; Zohoncon, TM; Zongo, AW; Zouré, AA | 1 |
| Alavian, SM; Anvar, A; Azizi-Saraji, A; Behnava, B; Namvar, A; Salimi, S; Sharafi, H | 1 |
| AbdAllah, M; Abdel Maksoud, MH; Abdelaziz, H; Ali, L; Cordie, A; Doss, W; El Garhy, N; El Serafy, M; Esmat, G; Khalil, M; Mohamed, R; Omar, H | 1 |
| Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S | 1 |
| Gan, T; Guo, M; Han, L; Leumi, S; Lu, J; Ngari, J; Tong, Y; Wang, L; Wang, Z; Xiang, X; Xie, Q; Zhong, J | 1 |
| Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Gaggar, A; Hsu, YC; Hu, TH; Jiang, D; Liu, CJ; Lo, GH; Massetto, B; Peng, CY; Sheen, IS; Suri, V; Tseng, KC; Wang, HY; Yang, J; Zhang, F | 1 |
| Chayama, K; Hayes, CN; Imamura, M; Tanaka, J | 1 |
| Anthony, D; Avihingsanon, A; Bennet, JA; Benson, CA; Brates, I; Cheinquer, N; Kityo, C; Kliemann, DA; Linas, B; Naggie, S; Nunes, EP; Robbins, G; Santana-Bagur, J; Scello, C; Smeaton, L; Solomon, SS; Son, A; Sowah, LA; Sulkowski, M; Supparatpinyo, K; Tebas, P; Van Schalkwyk, M; Wagner-Cardoso, S; Wimbish, C; Wyles, D | 1 |
| Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J | 1 |
| Bailey, H; Collins, IJ; Malik, F; Malyuta, R; Thorne, C; Volokha, A | 1 |
| AbdEl-Maksoud, HA; Alsaab, SM; El-Hamid, OA; El-Sorady, EM; Elharrif, MG | 1 |
| Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
| Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Huntley, R; Jimmerson, LC; Kiser, JJ; Mawhinney, S; Morrow, M; Roon, L; Rowan, SE; Salah, L; Tehrani, A; Wyles, D | 1 |
| El-Mehasseb, IM; El-Shafai, NM; Ibrahim, MM; Masoud, MS; Mersal, GAM; Ramadan, MS | 1 |
| Kao, JH; Liu, CH; Liu, CJ | 1 |
| Adinolfi, LE; De Lucia Sposito, P; Fusco, R; Gaglione, P; Izzi, A; Lumino, P; Maggi, P; Marrone, A; Messina, V; Nevola, R; Rega, R; Rinaldi, L; Sasso, FC; Simeone, F | 1 |
| Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI | 1 |
| Waked, I | 1 |
| Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Bae, SH; Chang, UI; Choi, JY; Han, JW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, J; Lee, SK; Lee, SW; Nam, H; Nam, SW; Song, DS; Song, MJ; Sung, PS; Yang, H; Yang, JM; Yoo, SH; Yoon, SK | 1 |
| Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW | 1 |
| Bova, SE; Freedman, SR; Pluckrose, DM; Szczepanik, A | 1 |
| Alavian, SM; Hajarizadeh, B; Hl Borba, H; Sabermahani, A; Sharafi, H; Tasavon Gholamhoseini, M | 1 |
| Ebell, M; Elshafie, S; Trivedi-Kapoor, R | 1 |
| Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Esteves, J; Forehand, J; Gradus, JL; Gui, J; Hoyt, JE; Huybrechts, K; Jiang, T; Ray, K; Rozema, L; Schnurr, PP; Shiner, B; Watts, BV | 1 |
| Abdine, HH; Aboras, SI; El-Yazbi, AF; Korany, MA; Ragab, MAA | 1 |
| Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
| Gowda, C; Honegger, JR | 1 |
| Kao, JH; Liu, CH | 1 |
| Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M | 1 |
| Chen, S; Dzakah, EE; Gong, P; Liu, S; Rashid, F; Sun, Q; Tang, S; Wang, H; Wang, J; Wu, J; Yang, X | 1 |
| Buti, M; Castellanos Fernández, MI; Chan, WK; Duseja, A; El-Kassas, M; Esmat, G; Gordon, SC; Hamid, S; Henry, L; Isakov, V; Lam, B; Méndez-Sánchez, N; Nader, F; Ong, JP; Papatheodoridis, G; Racila, A; Romero-Gómez, M; Stepanova, M; Yilmaz, Y; Younossi, I; Younossi, ZM; Yu, ML; Ziayee, M | 1 |
| Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE | 1 |
| Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D | 1 |
| Angelidakis, G; Granwehr, BP; Hosry, J; Jiang, Y; Mustafayev, K; Torres, HA; Yepez Guevara, E; Yibirin, M | 1 |
| Fernandes, F; Pereira, G; Perez, R; Piedade, J; Victor, L; Villela-Nogueira, CA | 1 |
| Anushree, N; Seetharaman, K; Venkatesh, V | 1 |
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
| Ajdarkosh, H; Amirkalali, B; Faraji, AH; Karbalaie Niya, MH; Khoonsari, M; Maadi, M; Motamed, N; Nikkhah, M; Safarnezhad Tameshkel, F; Sobrakhshankhah, E; Sohrabi, M; Vafaeimanesh, J; Zamani, F | 1 |
| Fu, X; Guo, M; He, YQ; Li, CY; Qiao, M; Ren, XD | 1 |
| Biering, SB; Chien, M; Dugast-Darzacq, C; Garzia, A; Graham, TGW; Jockusch, S; Ju, J; Meyer, C; Näär, AM; Nguyenla, X; Patel, DJ; Russo, JJ; Schaletzky, J; Stanley, S; Stroumza, J; Tao, C; Tuschl, T; Van Dis, E; Wang, X; Wehri, E; Xie, W; Yamashiro, LH; Zhu, C | 1 |
| Cordie, A; Esmat, G; Kamel, AM; Sabry, N | 1 |
| Agyemang, L; Anderson, J; Arnsten, J; Blalock, KL; Borsuk, C; Falade-Nwulia, O; Feinberg, J; Heo, M; Jacobsohn, V; Johnson, N; Karasz, A; Kim, AY; Litwin, AH; Luetkemeyer, AF; Lum, PJ; Mckee, MD; Mehta, SH; Meissner, P; Murray-Krezan, C; Norton, BL; Page, K; Pericot-Valverde, I; Roche, J; Stein, ES; Taylor, LE; Thomas, A; Tsui, JI; Wagner, K; Ward, JW; Wilkinson, S | 1 |
| Li, J; Wang, L; Xie, W; Zhou, Y; Zhu, X | 1 |
| Abdel Alem, S; Abdelbary, MS; Cordie, A; El Garhy, N; El Khateeb, E; Elsharkawy, A; Esmat, G; Fouad, R; Khalil, M | 1 |
| Acosta-López, S; Borgia, SM; Buti, M; Di Marco, V; Fenech, M; Fraser, C; Garcia-Retortillo, M; Guerra-Veloz, MF; Hernández, C; Martins, A; Mertens, M; Milella, M; Milligan, S; Morano Amado, LE; Ntalla, I; O'Loan, J; Ramji, A; Ramroth, H; Rodriguez-Tajes, S; Teti, E; Vanstraelen, K; Wedemeyer, H | 1 |
| Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J | 1 |
| Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK | 1 |
| Katz, R; Mod, AT | 1 |
| Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A | 1 |
| Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS | 1 |
| Chen, CY; Hung, HY; Lai, HH; Lin, HC | 1 |
| Hung, A; Seetasith, A; Wong, WB; Zullig, LL | 1 |
| Bhattacharya, D; Brates, I; Kreter, B; Linas, B; Robbins, GK; Smeaton, L; Solomon, S; Sowah, LA; Sulkowski, M; Wagner-Cardoso, S | 1 |
| Aktas, H; Burger, D; de Knegt, R | 1 |
| Balagopal, A; Bowden, K; Leep-Lazar, J; Quinn, J; Ribeiro, RM; Sachithanandham, J; Sulkowski, MS; Ward, K | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Higashiyama, S; Kageyama, K; Kawabe, J; Kawada, N; Kawamura, E; Kotani, K; Kozuka, R; Motoyama, H; Odagiri, N; Tamori, A; Uchida-Kobayashi, S; Yamamoto, A; Yoshida, A; Yukawa-Muto, Y | 1 |
| Byrns, J; Kiser, JJ; Maziarz, E; Naggie, S; Narayanasamy, S; Steinbrink, JM; Wolfe, CR | 1 |
| Bourgeois, S; Foster, GR; Gerken, G; Hernandez, C; Jacobson, IM; Mathurin, P; Osinusi, A; Ryder, SD; Scherbakovsky, S; Tedesco, D; Thuluvath, P; Vanstraelen, K | 1 |
| Chang, ML; Chen, CJ; Chen, YC; Chien, RN; Hsu, CW; Huang, YH; Lin, CY; Shen, YH | 1 |
| Hechter, V; Kayuni, N; Saayman, E; Sonderup, MW | 1 |
| Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ | 1 |
| Hampejskova, L; Hasnain, A; Shah, S | 1 |
| Azzeri, A; Dahlui, M; Jaafar, H; McDonald, SA; Mohamed, R; Shabaruddin, FH | 1 |
| Bukh, J; Fahnøe, U; Fernandez-Antunez, C; Gottwein, JM; Mikkelsen, LS; Ramirez, S; Wang, K | 1 |
| Charlton, C; Hlavay, BA; Klein, MB; Ogando, N; Power, C; Stapleton, JT; Zhuo, R | 1 |
| Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H | 1 |
| Mahgoub, A; Schulz, P; Wiginton, A | 1 |
| Awasthi, A; Deep, A; Goel, A; Katiyar, H; Kumar, A; Kumar, V; Rungta, S; Tiwari, P | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Buonomo, AR; Cattaneo, L; De Filippis, F; Ercolini, D; Gentile, I; Gison, F; Maraolo, AE; Pinchera, B; Schiano Moriello, N; Scotto, R; Viceconte, G; Villari, R; Zappulo, E | 1 |
| Bhagat, N; Charak, S; De, A; Duseja, A; Goel, K; Premkumar, M; Rathi, S; Sharma, A; Singh, V; Taneja, S; Verma, N | 1 |
| Domingo, H; Moser, A; Patel, S | 1 |
| Abdel-Aziz, MM; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA | 1 |
| Hsin, YH; Huang, CW; Ko, CY; Tsai, QZ; Tsai, YC; Yu, ML | 1 |
| Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E | 1 |
| Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N | 1 |
| Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME | 1 |
| Al-Qahtani, SD; Alalawy, AI; Alatawi, K; El-Mehasseb, IM; El-Shafai, NM; Farrag, MA; Nada, AI | 1 |
| Shin, HP | 1 |
| Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT | 1 |
| Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L | 1 |
| Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ | 1 |
| Akhtar, MF; Anwar, F; Khan, A; Shah, SA; Yasmeen, S | 1 |
| Kampmann, C; Weiland, O; Wejstål, R; Westin, J; Ydreborg, M | 1 |
| Martinello, M; Matthews, GV; Naggie, S; Rockstroh, JK | 1 |
| Ahmad, B; Ahmad, J; Ahmad, L; Bashir, K; Chen, TW; Hameed, H; Haq, I; Haq, M; Hussain, K; M Aljowaie, R; Malik, G; Maryam, A; Mohsen Abougazia, E; Ullah, A | 1 |
| Anuradha, K; Ismal, K; Lakshmi, J; Sahay, M | 1 |
| Alonzo-García, C; Contreras, AG; Fernández-Ramírez, A; García-Juárez, I; Romero-Hernández, F; Ruiz, I; Servín-Rojas, M | 1 |
| Duong, V; Guo, M; Han, L; Liu, C; Lu, J; Nouhin, J; Tong, Y; Xiang, X; Xie, Q; Zhong, J | 1 |
| Alhmoud, JF; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA | 1 |
| Collins, M; Conway, B; Dylla, DE; Khan, T; Marcinak, J; Martinez, A; Saget, B | 1 |
| Luetkemeyer, AF; McDonell, C; McKinney, J; Morris, MD; Price, JC; Thawley, R | 1 |
| Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M | 1 |
| Assem, NM; Atoom, AM; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA | 1 |
| Daryani, N; Imam, U; Mumtaz, F; Parkash, A | 1 |
| Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA | 1 |
| Awad, J; Balsara, K; Brinkley, DM; Brown Sacks, S; Danter, M; Darragh, C; Fowler, R; Lindenfeld, J; Menachem, J; O'Dell, H; Ooi, H; Perri, R; Punnoose, L; Ruzevich-Scholl, S; Schlendorf, K; Shah, A; Smith, S; Wigger, M; Zalawadiya, SK | 1 |
| Bahuguna, P; Chugh, Y; Dhiman, RK; Premkumar, M; Prinja, S; Singh Grover, G | 1 |
| Grasso, AG; Loiacono, S; Maestro, A; Maximova, N; Sonzogni, A; Zanon, D | 1 |
| Anis, AH; Azim, T; Chowdhury, EI; Faruque, MO; Janjua, NZ; Kabir, A; Khan, SI; Rahman, M; Reza, M; Sarker, MS; Shafiq, TKI | 1 |
| Afzal, MS; Ahmed, H; Ali, M; Haqqi, A; Khalid, M; Khurram, M; Munir, R; Shah, ZH; Zaid, M | 1 |
| Abutidze, A; Adamia, E; Afdhal, N; Arora, S; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kuchuloria, T; Lagvilava, M; Metreveli, D; Nasrullah, M; Sergeenko, D; Shadaker, S; Sharvadze, L; Skaggs, B; Thornton, K; Tsertsvadze, T; Zeuzem, S | 1 |
| Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V | 1 |
| Brown, CH; Fang, LJ; Goldberg, R; Graydon, M; Himelhoch, S; Kreyenbuhl, J; Slade, E; Travaglini, LE | 1 |
| Mandimika, C; Ogbuagu, O | 1 |
| Blackard, JT; Horn, PS; Karns, R; Kong, L; Kottilil, S; Rouster, SD; Shata, MT; Sherman, KE | 1 |
| Alonso López, S; Guerra Romero, AR; Pérez Figueras, M | 1 |
| Barclay, ST; Boyle, A; Datta, S; Heydtmann, M; Marra, F; Peters, E; Priest, M; Ritchie, T | 1 |
| Alavi, M; Danta, M; Dore, GJ; Hajarizadeh, B; He, S; Lockart, I | 1 |
| Hikita, H; Takehara, T | 1 |
| Al-Ahmed, SH; Aldrazi, FA; Alfouzan, WA; Alsuliman, SA; Bazzi, AM; Haque, S; Rabaan, AA | 1 |
| Farcomeni, A; Gioia, S; Nardelli, S; Ridola, L; Riggio, O; Rosati, D | 1 |
| Cui, LY; Liu, LD; Nan, YM; Zhao, W | 1 |
| Lazarus, JV; Lens, S | 1 |
| Giannini, EG; Indolfi, G | 1 |
| Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M | 1 |
| Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH | 1 |
| Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J | 1 |
| Dholaria, B; Juskevicius, R; Moreno Vanegas, YA | 1 |
| Cazorla, JM; Garcia, T; Mazuecos, A; Merino, MJ; Moreno-Ramirez, M; Naranjo, J; Vigara, LA; Villanego, F | 1 |
| Heinz, A; Johnson, NL; Lasser, KE; Lee, KS; Quintiliani, L; Truong, V; Xuan, Z | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Brennfleck, FW; Brunner, SM; Evert, K; Junger, H; Knoppke, B; Melter, M; Schlitt, HJ; Weigand, K | 1 |
| Abdel Moneim, A; Mabrouk, D; Mahmoud, B; Suleiman, HA; Zaky, MY | 1 |
| Nabavi, N; Pourahmad, J; Yousefsani, BS | 1 |
| Banga, J; Nagarakanti, S; Nizami, S; Portilla, M; Slim, J; Swaminathan, S | 1 |
| Haseltine, WA | 1 |
| Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC | 1 |
| Angelico, M; Aragri, M; Carioti, L; Ceccherini-Silberstein, F; Di Maio, VC; Lenci, I; Milana, M; Perno, CF; Svicher, V | 1 |
| El-Sayed, HM; Elmasry, MS; Hassan, WS; Shalaby, A; Zidan, DW | 1 |
| Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P | 1 |
| Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL | 1 |
| Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M | 1 |
| Khalil, H; Kim, NG; Kullar, R; Saab, S | 1 |
| Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR | 1 |
| Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F | 1 |
| Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C | 1 |
| Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N | 1 |
| Barbera, F; Conaldi, PG; Curcio, G; Gallo, A; Pietrosi, G; Russelli, G; Tuzzolino, F; Vizzini, G; Volpes, R | 1 |
| Barclay, ST; de Bruin, M; Dillon, JF; Donnan, PT; Fraser, A; Hapca, A; Inglis, SK; Radley, A | 1 |
| Bruchfeld, A | 1 |
| Bonacini, M; Brainard, DM; De-Oertel, S; Flamm, SL; Gane, EJ; Gordon, SC; Huang, J; Hyland, RH; Kirby, BJ; Landis, CS; Lawitz, E; Maliakkal, BJ; Ortiz-Lasanta, G; Osinusi, AO; Robson, R; Zhang, J | 1 |
| Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
| Aschenbrenner, DS | 4 |
| Applegate, TL; Barash, D; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Martinello, M; Matthews, GV; Uprichard, SL; Walsh, K; Yardeni, D | 1 |
| Averhoff, F; Butsashvili, M; Dvali, S; Gamkrelidze, A; Gvinjilia, L; Kamkamidze, G; Metreveli, D; Morgan, J; Nasrullah, M; Rukhadze, T; Shadaker, S | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S | 1 |
| Devi, S | 1 |
| Blackard, JT; Celentano, DD; Jamieson, DJ; King, CC; Klein, RS; Kong, L; Lin, D; Mayer, KH; Ngwaga, T; Schoborg, C; Sobel, JD; Tavis, JE; Taylor, LE | 1 |
| Chander, PN; Chugh, S; Singh, J; Solanki, S; Wolf, DC | 1 |
| Gauci, J; Gerada, J; Micallef, S | 1 |
| Byrd, K; D'Agata, EMC; Kalligeros, M; Martin, P; Mylonakis, E; Shehadeh, F; Shemin, D | 1 |
| Burger, DM; Colbers, A; Drenth, JPH; Freriksen, JJM; Greupink, R; Meijerhof, M; Russel, FGM; van Drongelen, J | 1 |
| Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
| Janjua, NZ; Klein, MB; Wong, S; Young, J | 1 |
| Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y | 1 |
| Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T | 1 |
| Bayer, J; Burton, J; Dodge, J; Ghobrial, M; Klein, C; Mohan, S; Niemann, CU; Rubin, RA; Terrault, NA; Trotter, J; Verna, E; Victor, D | 1 |
| Barralon, M; Bijl, M; Cavenaugh, C; Chasela, CS; Chew, KW; Drame, N; Freiman, MJ; Gandhi, MM; Kyi, KP; Lwin, AA; Marange, F; Min Thaung, Y; Minior, T; Mohamed, S; Naing, AY; Rosen, S; Sanne, I; Sein, YY; Thura, S; Thwin, HT; van der Horst, C; Wose Kinge, C; Xulu, T | 1 |
| Bogen, DL; Bunge, KE; Chappell, CA; Gaggar, A; Hillier, SL; Kirby, BJ; Krans, EE; Macio, IS; Meyn, LA; Scarsi, KK; Suri, V | 1 |
| Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C | 1 |
| Masuda, T; Miyasaka, A; Okamoto, H; Suzuki, A; Takikawa, Y; Yoshida, Y | 1 |
| Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Dee, YKS; Linn, YH; Lwin, KM | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Rai, P; Rungta, S; Tiwari, P; Verma, A | 1 |
| Abd El-Maksoud, MDE; Ahmed, AE; Ahmed, OM; El-Garem, H; Gamal, A; Sakr, AA | 1 |
| Bittar, C; Chen, S; Fernandes Campos, GR; Harris, M; Martinelli, ALC; Pereira, LRL; Rahal, P; Souza, FF; Vilela Rodrigues, JP; Ward, J | 1 |
| Mendizabal, M; Piñero, F; Ridruejo, E; Silva, M | 1 |
| Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH | 1 |
| Ahmed-Belkacem, A; Chevaliez, S; Demontant, V; Donati, F; Fourati, S; François, M; N'Debi, M; Pawlotsky, JM; Poiteau, L; Rodriguez, C; Ruiz, I; Scoazec, G; Soulier, A | 1 |
| Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH | 1 |
| Chen, S; Song, W; Yi, Z; Yuan, Z; Zhang, Y | 1 |
| Farooq, MO; Malik, K; Mengal, FUA; Salim, A | 1 |
| Choi, IS; Kim, KM; Shim, SG | 1 |
| Bhangui, P; Choudhary, NS; Rastogi, A; Saigal, S; Saraf, N; Soin, AS; Thiagrajan, S | 1 |
| Ahn, SH; Amarsanaa, J; Baatarkhuu, O; Badamsuren, D; Batbayar, P; Choijamts, N; Enkhtuya, D; Gantuul, C; Gegeebadrakh, B; Han, KH; Kim, DY; Lee, JS; Naranzul, N; Otgonbayar, R; Otgonbold, J; Saruul, BU; Tuvshinbayar, N; Ulzmaa, G | 1 |
| Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T | 1 |
| Amara, D; Blumberg, E; Dove, L; Durand, CM; Emond, J; Fishbein, T; Florman, S; Grab, J; Haydel, B; Huprikar, S; Husson, J; Kottilil, S; Luetkemeyer, AF; Masur, H; Olthoff, K; Peters, MG; Rogers, R; Smith, C; Stock, PG; Sulkowski, MS; Terrault, N | 1 |
| Chang, JM; Chen, SC; Chiu, YW; Chuang, WL; Dai, CY; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JC; Huang, JF; Hung, TS; Hwang, SJ; Lee, JJ; Liang, PC; Lin, WY; Lin, YH; Liu, TW; Niu, SW; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Chang, JM; Chen, SC; Chiu, YW; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JC; Huang, JF; Hwang, SJ; Jang, TY; Lee, JJ; Liang, PC; Lin, YH; Lin, ZY; Niu, SW; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iliescu, L; Istratescu, D; Manuc, M; Pop, CS; Preda, CM; Tieranu, C; Voiosu, T | 1 |
| Morillo-Verdugo, R; Sicras-Mainar, A | 1 |
| Ampuero, J; García-García, Y; García-Monzón, C; González-Rodríguez, Á; Majano, P; Marañón, P; Molina-Jiménez, F; Múñoz-Hernández, R; Rey, E; Romero-Gómez, M | 1 |
| Aregay, A; Björkström, NK; Cornberg, M; Deterding, K; Du, Y; Hardtke, S; Hardtke-Wolenski, M; Hengst, J; Khera, T; Manns, MP; Port, K; Steinmann, E; Strunz, B; Todt, D; Wedemeyer, H | 1 |
| Maajani, K; Majd Jabbari, S; Merat, S; Poustchi, H; Sepanlou, SG | 1 |
| Abdullatif, H; Alem, SA; El-Karaksy, H; El-Raziky, MS; Eldeen, HG; Mogahed, EA; Nagy, A; Yasin, NA | 1 |
| Mühlbacher, AC; Sadler, A | 1 |
| Callegaro, FS; de Camargo Vieira, MC; Gonçalves, WRB; Guerra, RA; Lazaretti-Castro, M; Maeda, SS | 1 |
| Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R | 1 |
| Doi, A; Hikita, H; Kodama, T; Sakamori, R; Shigekawa, M; Shinkai, K; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R; Yamada, T | 1 |
| Harrison, M; Ho, H; Janjua, NZ; Law, MR; McGrail, KM | 1 |
| Bair, MJ; Chang, CC; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| Bilal, M; Farooq, N; Hussain, N; Maqsood, M; Rajoka, MSR | 1 |
| Aghemo, A; Solitano, V | 1 |
| Balkan, S; Bunreth, V; Craig, J; Dousset, JP; Jolivet, P; Le Paih, M; Marquardt, T; O'Keefe, D; Samley, K; Zhang, M | 1 |
| Ehl, S; Maccari, ME; Speckmann, C; Thalhammer, J; Wegehaupt, O | 1 |
| Ahmed, A; Davis, MM; Dekker, CL; Du, H; Fram, BJ; Furman, D; Glenn, JS; Grant, PM; Khatri, P; Lopez Angel, CJ; Maecker, HT; Nguyen, T; Perez, K; Pham, EA; Rosenberg-Hasson, Y; Vallania, F | 1 |
| Derayea, SM; Hamad, AE; Mohammed, BS | 1 |
| Martin, P; McQuaid, T; Sise, ME | 1 |
| Draper, B; Hellard, M; Pedrana, A | 1 |
| Burden, AM; Burkard, T; Hayes, KN; Tadrous, M; Weiler, S | 1 |
| Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U | 1 |
| Chang, KC; Chang, TS; Chen, WM; Chiu, WN; Ding, YJ; Hsieh, YY; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW | 1 |
| Inoue, J; Iwata, T; Kakazu, E; Masamune, A; Ninomiya, M; Sano, A; Sato, K; Tsuruoka, M | 1 |
| Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N | 1 |
| Ansari, MA; Aranday-Cortes, E; Barnes, E; Benselin, J; Bibby, DF; Bradshaw, D; Brown, A; da Silva Filipe, A; Healy, B; Hudson, E; Irving, WL; Manso, CF; Mbisa, JL; McLauchlan, J; Singer, JB; Smith, DA; Thomson, EC; Troke, P | 1 |
| Bergquist, K; Fried, MW; Kort, JJ; Larsen, L; Magee, A; Michael, LC; Nelson, DR; Patel, CB; Peter, JA; Schnell, GL; Schuster, L; Sidhu, GS; Tamashiro, R; Tripathi, RL; Wang, GP; Whitlock, JA | 1 |
| Applegate, TL; Bhagani, S; Bruneau, J; Dore, GJ; Feld, JJ; Gane, E; Grebely, J; Hellard, M; Ingiliz, P; Kim, A; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Petoumenos, K; Rauch, A; Rockstroh, J; Shaw, D; Thurnheer, C; Van der Valk, M | 1 |
| Bai, L; Chen, L; Du, L; He, M; Kang, S; Li, C; Ma, F; Tang, H | 1 |
| D'Antiga, L; Di Giorgio, A; Indolfi, G; Nicastro, E; Norsa, L | 1 |
| Chang, KC; Chang, TS; Chen, WM; Hsieh, YY; Huang, YT; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW | 1 |
| Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA | 1 |
| Bhati, C; Carroll, N; Cotterell, A; Gupta, G; Ijioma, S; Kamal, L; Kang, L; Khan, A; Kimball, P; King, A; Kumar, D; Levy, M; Mitchell, K; Moinuddin, I; Patterson, J; Sharma, A; Shinbashi, M; Sterling, R; Yakubu, I; Zhang, Y | 1 |
| Fraser, H; Havens, JR; Hoven, A; Lofwall, M; Schaninger, T; Staton, M; Vickerman, P; Walsh, SL; Young, AM | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS | 1 |
| Bloom, DE; Khoury, A; Srinivasan, V | 1 |
| Pang, L; Tang, H; Tang, Y; Xu, D; Xu, P; Yang, X; Zhang, G | 1 |
| Lonze, BE; Parent, B; Richter, BI | 1 |
| Brainard, DM; Chung, R; Fierer, DS; Hollabaugh, K; Hughes, M; Kim, A; Kiser, JJ; Macbrayne, C; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Symonds, B | 1 |
| Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R | 1 |
| Chowdhury, R; Tsen, A | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK | 1 |
| Adeyemi, O; Brainard, DM; Bräu, N; Daar, ES; Doehle, B; Huang, KC; Kim, AY; Kottilil, S; Luetkemeyer, A; McHutchison, JG; McNally, J; Mogalian, E; Naggie, S; Osinusi, A; Ruane, P; Sulkowski, M; Workowski, K; Wyles, D | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Deming, P; Martin, MT | 1 |
| Angarano, G; Bruno, G; Milella, M; Saracino, A | 1 |
| Hirayama, A; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamana, Y; Yoda, S | 1 |
| Bhagani, S; Boesecke, C; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Ingiliz, P; Lutz, T; Nelson, M; Rockstroh, JK; Yun, C; Zheng, W | 1 |
| Abd-Elsalam, S; Ahmed, OA; Hassan A Fouad, M; Hawash, N; Kaisar, HH; Rizk, F; Samir, H; Shabana, SST | 1 |
| Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Maggi, P; Martinelli, C; Nicolini, LA; Quirino, T; Ricci, E; Squillace, N; Taramasso, L | 1 |
| Balkan, II; Mete, B; Ozaras, R; Tabak, F; Yemisen, M | 1 |
| Haba, S; Kobayashi, Y; Matsuda, S; Miyagishima, T; Morikawa, K; Nakano, S; Oda, H; Sakamoto, N; Sarashina, K; Sogabe, S; Takahashi, K; Takahashi, T; Terashita, K; Yamamura, T; Yoshikawa, A | 1 |
| Hunt, S; Kottilil, S; Stepanova, M; Sulkowski, M; Wyles, D; Younossi, ZM | 1 |
| Gonzalez-Estrada, A; Sankhyan, P | 1 |
| Aung, ST; Bwa, AH; Hlaing, NKT; Kyaw, AMM; Mitrani, RA; Phyo, WW; Reddy, KR; Serper, M; Win, KM | 1 |
| Arencibia, AC; Baliellas, C; Blasco, A; Cabezas, J; Calleja, JL; Carrión, JA; Castellote, J; Castells, L; Castro, MA; Crespo, J; Cuervas-Mons, V; de Artaza, T; Diago, M; Fernández, I; Forné, M; Forns, X; Gallego, A; García-Samaniego, J; Gea-Rodríguez, F; Giráldez, Á; Gómez, A; Hontangas, V; López-Núñez, C; Mariño, Z; Montero, JL; Moreno, JM; Morillas, R; Narváez, I; Pascasio-Acevedo, JM; Pascual, S; Prieto, M; Romero-Gómez, M; Sánchez-Antolín, G; Sánchez-Ruano, JJ; Torras, X; Turnes, J; Vergara, M | 1 |
| Angiola, A; Caruso, A; Casari, S; Castelli, F; Festa, E; Gargiulo, F; Lanza, P; Nasta, P; Odolini, S; Rodella, A; Urbinati, L; Vavassori, A; Viganò, M; Zaltron, S | 1 |
| Heil, EL; Hoke, KS; Mattingly Ii, TJ | 1 |
| Alfieri, R; Andreoni, M; Angelico, M; Antonucci, FP; Babudieri, S; Bernardini, S; Biliotti, E; Bolis, M; Calvaruso, V; Casalino, P; Ceccherini-Silberstein, F; Cento, V; Cerrone, M; Craxì, A; D'Arminio Monforte, A; Danieli, E; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gianserra, L; Guedj, J; Lenci, I; Magni, CF; Melis, M; Menzaghi, B; Micheli, V; Nguyen, THT; Nicolini, LA; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Puoti, M; Quirino, T; Rizzardini, G; Romagnoli, D; Sarmati, L; Siciliano, M; Taliani, G; Teti, E | 1 |
| Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Amblard, F; Amiralaei, S; Cho, JH; Coats, SJ; Ehteshami, M; Li, H; Lu, X; McBrayer, TR; Ozturk, T; Schinazi, RF; Shelton, JR; Stanton, R; Zhang, H; Zhou, L | 1 |
| Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J | 1 |
| Bielen, R; Bourgeois, S; Brixko, C; Cool, M; Cools, W; D'heygere, F; De Galocsy, C; Decaestecker, J; Janssens, F; Moreno, C; Mulkay, JP; Nevens, F; Robaeys, G; Van Overbeke, L; Van Steenkiste, C; Van Vlierberghe, H; Vanwolleghem, T; Verlinden, W | 1 |
| Sise, ME | 1 |
| Sokol, R | 1 |
| Mauss, S; Tacke, F | 1 |
| Goda, Y; Hakamatsuka, T; Hosoe, J; Kamakura, H; Maruyama, T; Masada, S; Tokumoto, H; Tsujimoto, T; Uchiyama, N | 1 |
| Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V | 1 |
| Bhayani, V; Desai, P; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Patel, S | 1 |
| Barra, M; Caldeira, D; Costa, J; Duarte, MM; Ferreira, JJ; Gonçalves, N; Pinto, FJ; Rodrigues, FB; Sterrantino, C | 1 |
| Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P | 1 |
| Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S | 1 |
| Altice, FL; Barnard, T; Filippovych, S; Mazhnaya, A; Meteliuk, A; Zelenev, A | 1 |
| Cheema, HA; Hashmi, MA | 1 |
| Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D | 1 |
| Baz, M; Harris, DD; Shafii, AE | 1 |
| Antonini, TM; Botta-Fridlund, D; Canva, V; Coilly, A; De Ledinghen, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Leroy, V; Pageaux, GP; Perré, P; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Taburet, AM; Veislinger, A | 1 |
| Abd-Elsalam, S; Ahmad, YK; Badawi, R; Elfert, A; Sharaf-Eldin, M; Soliman, S | 1 |
| Reddy, KR; Weinberg, EM | 1 |
| Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
| Fulco, PP; Lavoie, SR; Sterling, RK | 1 |
| Ikeda, A; Ikeda, K; Inagaki, N; Kokuryu, H; Marusawa, H; Seno, H; Takahashi, K; Takai, A; Ueda, Y | 1 |
| Brancaccio, G; Cantone, M; Ceccherini-Silberstein, F; Fabeni, L; Frigeri, F; Gaeta, GB; Genderini, F; Perno, CF; Pinto, A; Rizzo, V; Sorbo, MC | 1 |
| Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A | 1 |
| Chahine, EB; Childs-Kean, LM; Kelley, D | 1 |
| Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA | 1 |
| Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM | 1 |
| Kalal, C; Mohanka, R; Patel, P; Shah, S; Shukla, A; Vora, M | 1 |
| Brainard, DM; Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Hsu, YC; Hu, TH; Jiang, D; Knox, SJ; Liu, CJ; Lo, GH; Massetto, B; McHutchison, JG; Osinusi, A; Peng, CY; Sheen, IS; Tseng, KC; Wang, HY; Yang, JC; Yun, C | 1 |
| Assoumou, SA; Horsburgh, CR; Huang, W; Linas, BP; Young, K | 1 |
| Crutcher, EL; Greene, EM; Lenz, DU | 1 |
| Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK | 1 |
| Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U | 1 |
| Carlton-Smith, C; Chung, RT; Holmes, JA; Kim, AY; Lauer, GM; Lidofsky, A; Naggie, S | 1 |
| Agarwal, K; Carey, I; Lampejo, T | 1 |
| Chen, TY; Dong, J; Gao, H; He, YL; Hu, CH; Liu, JF; Ren, DF; Yan, TT; Yang, SJ; Yang, Y; Zhao, YR; Zhu, L | 1 |
| Blackard, JT; Hammerstad, SS; Homann, D; Kong, L; Lombardi, A; Tomer, Y | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Fabbri, G; Libertone, R; Notari, S; Tempestilli, M | 1 |
| Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H | 1 |
| El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A | 1 |
| Elfert, AA | 1 |
| Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Scott, LJ | 1 |
| Khattak, MA; Kothapalli, A | 1 |
| Ansari, MA; Barnes, E; Bonsall, D; Bowden, R; Brown, A; Ip, CLC; Magri, A; Nguyen, D; Piazza, P; Simmonds, P; Smith, D; Trebes, A | 1 |
| Doi, A; Furuta, K; Hikita, H; Imai, Y; Kai, Y; Kodama, T; Mita, E; Ohkawa, K; Sakamori, R; Tahata, Y; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R | 1 |
| Ali, M; Aziz, H; Raza, A; Shinwari, ZK; Zia, A; Zia, M | 1 |
| Desai, K; Desai, N; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Shah, J | 1 |
| Afdhal, N; Babusis, D; Curry, MP; Kirby, B; Mathias, A; McHutchison, JG; Murakami, E; Park, Y; Ray, AS; Wang, T | 1 |
| Fan, R; Hou, J; Liang, X; Sun, J | 1 |
| Ferenci, P | 1 |
| Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P | 1 |
| Bair, N; Bowring, MG; Brown, DM; Chattergoon, MA; Desai, NM; Durand, CM; Massaccesi, G; Naqvi, FF; Ostrander, D; Reyad, A; Segev, DL; Sugarman, J; Sulkowski, M; Wesson, R | 1 |
| Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T | 1 |
| Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R | 1 |
| Goldstein, DB; Kleinstein, SE; Naggie, S; Shea, PR; Stamm, LM; Sulkowski, M | 1 |
| Dashti-Khavidaki, S; Khalili, H; Nasiri-Toosi, M | 1 |
| Ansari, MA; Barnes, E; Bowden, R; Hudson, E; Klenerman, P; Marchi, E; Mclean, A; Pedergnana, V; Ramamurthy, N; Spencer, CCA | 1 |
| Baumgarten, A; Boesecke, C; Busch, HW; Christensen, S; Daeumer, M; Hueppe, D; Ingiliz, P; Luebke, N; Lutz, T; Mauss, S; Rockstroh, JK; Sarrazin, C; Schewe, K; Schulze Zur Wiesch, J; Simon, KG; Timm, J; Vermehren, J; von Felden, J | 1 |
| More, B | 1 |
| Aljudaibi, B; Bilodeau, M; Congly, SE; Faisal, N; Ghali, MP; Hirch, G; Hussaini, T; Lilly, LB; Ma, MM; Yoshida, EM | 1 |
| Benson, AA; Lederman, N; Safadi, R; Wolf, D | 1 |
| Hu, J; Li, C | 1 |
| Adragão, T; Birne, R; Bruges, M; Carvalho, L; Chagas, C; Jorge, C; Lebre, L; Machado, D; Matias, P; Nascimento, C; Querido, S; Weigert, A | 1 |
| Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML | 1 |
| Basile, M; Cicchetti, A; Drago, C; Favaretti, C; Kheiraoui, F; Rolli, FR; Ruggeri, M | 1 |
| Reinke, T | 1 |
| Abbas, B; Asem, N; Elsharkawy, A; Esmat, G; Gomaa, A; Hassany, M; Maged, A; Mehrez, M; Mostafa, Z; Soliman, M | 1 |
| Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM | 1 |
| Cázares-Cortázar, A; Gaytán-Martínez, J; Gómez-Torres, ME; Martínez-Rodríguez, ML; Mata-Marín, JA; Ocaña-Mondragón, A; Ribas-Aparicio, RM; Uribe-Noguez, LA | 1 |
| Boldt, M; Hassan, MA; Huepfel, W; Lake, JR; Shaukat, AP; Tierney, AR; Wang, Q | 1 |
| Aggarwal, R; Chen, Q; Chhatwal, J; Goel, A | 1 |
| Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR | 1 |
| Summers, BB | 1 |
| Berg, CP; Berg, T; Blessin, U; Engelmann, C; Grottenthaler, JM; Harrer, E; Hinterleitner, C; Lauer, UM; Malek, NP; Pathil, A; Sarrazin, C; Scholten, S; Schott, E; Seybold, U; Spengler, U; Steurer, M; Stremmel, W; von Hahn, T; Wedemeyer, H; Welker, MW; Werner, CR | 1 |
| Sadler, MD | 1 |
| Christensen, S; Sarrazin, C; Schulze Zur Wiesch, J; Vermehren, J; von Felden, J | 1 |
| Chen, L; Li, B; Ma, L; Qing, J; Zhai, PB; Zhang, LQ | 1 |
| Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G | 1 |
| Abd Alla, MDA; Al-Azhari, SS; Dawood, RM; El Awady, MK; Elhawary, MA; Galal, AGM | 1 |
| Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R | 1 |
| Enomoto, N; Maekawa, S | 1 |
| Chu, TC; Fasanmi, EO; MacDonald, BR; Moore, JD; Ojha, RP; Stewart, RA | 1 |
| Abd Elaziz, D; Aiuti, A; Appleby, J; Barzaghi, F; Bernardo, ME; Boeri, E; Calbi, V; Calzatini, F; Canarutto, D; Casiraghi, M; Cestone, E; Cicalese, MP; Ciceri, F; Consiglieri, G; Darin, S; Dionisio, F; Ferrua, F; Finazzi, R; Gabaldo, M; Lucano, C; Marktel, S; Mieli-Vergani, G; Migliavacca, M; Recupero, S; Tucci, F | 1 |
| Boeker, KHW; Buggisch, P; Günther, R; Hüppe, D; Maasoumy, B; Manns, MP; Mauss, S; Müller, T; Sarrazin, C; Vermehren, J; Wedemeyer, H; Zimmermann, T | 1 |
| Hamano, T; Inoue, M; Someda, H; Tachibana, N; Tsuzaki, K | 1 |
| Hill, L; Kerr, J; Mansour, M | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Chu, TC; MacDonald, BR; Marcus, JL; Ojha, RP | 1 |
| Herrera, JL; Marshall, MC | 1 |
| Abdel-Lateef, MA; Ali, R; Derayea, SM; Omar, MA | 1 |
| Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N | 1 |
| Chua, JV; Claeys, K; Heil, EL; Hynicka, LM; Vega, AD | 1 |
| Jacobson, IM | 1 |
| Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G | 1 |
| Kottilil, S; Mathur, P; Wilson, E | 1 |
| Domalakes, E; He, L; Lee, GT; Mason, CW; Parrott, J; Pfeifer, E; Zhou, H | 1 |
| Aghemo, A; Craviotto, V; Lamonaca, L; Lleo, A | 1 |
| Arai, M; Chiba, T; Kanda, T; Kato, N; Maruyama, H; Miho, K; Mochizuki, H; Nakamura, M; Ogasawara, S; Omata, M; Ooka, Y; Shuntaro, O; Suzuki, E; Yasui, S; Yokosuka, O | 1 |
| Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M | 1 |
| Aziz, A; Durazo, F; Hanna, RM; Latt, N; Mikhail, MM; Mitry, A; Saab, S; Sahota, A; Yanny, B | 1 |
| Dupuy, CA; Glotz, D; Parlati, L; Pol, S; Sirmai, L | 1 |
| Almeida, J; Arrelaro, R; Cintra, M; Corrêa, B; Cunha-Silva, M; Lopes, T; Lorena, S; Mazo, D; Rabello, M; Sevá-Pereira, T; Torino, AB; Vaz, N | 1 |
| Costa, C; D'Ascoli, GL; De Rosa, S; Focà, A; Indolfi, C; Liberto, MC; Mazzitelli, M; Pisani, V; Raffetti, E; Sabatino, J; Strazzulla, A; Torti, C | 1 |
| Biggs, BA; Kanhutu, K; Sasadeusz, J; Schulz, TR; Watkinson, S | 1 |
| Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB | 1 |
| Morrison, C | 1 |
| Brainard, DM; McHutchison, JG; Stamm, LM | 1 |
| Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S | 1 |
| Abdurakhmanov, D; Bakulin, I; Brainard, DM; Burnevich, E; Chulanov, V; Gankina, N; Hyland, RH; Isakov, V; Ivashkin, V; Kozhevnikova, G; Lagging, M; Lu, S; McNally, J; Morozov, V; Nurmukhametova, E; Romanova, S; Svarovskaia, ES; Weiland, O; Zhdanov, K; Zhuravel, S | 1 |
| Zeuzem, S | 1 |
| Muljono, DH | 1 |
| Alcazer, V; Charre, C; Cotte, L; Miailhes, P; Ramière, C | 1 |
| Bakr, MA; El Maghrabi, HM; Elmowafy, AY; Elwasif, SM; Zahab, MA | 1 |
| Kimura, K | 1 |
| Laique, SN; Vargas, HE | 1 |
| Clément, V; Raimond, V | 1 |
| Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I | 1 |
| Bastos, FI; da Fonseca, EM; Shadlen, K | 1 |
| Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R | 1 |
| Dellay, B; Hess, GP; Israni, AK; Ray Kim, W; Sexter, A; Wang, JH | 1 |
| Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H | 1 |
| Brown, A; Dufour, JF; Gordon, SC; Mauss, S; Mensa, FJ; Pilot-Matias, T; Poordad, F; Rodrigues, L; Stoehr, A; Weiland, O; Weilert, F; Wyles, D; Yao, B; Zhang, Z | 1 |
| Brainard, DM; Gao, Z; Huang, R; Jiang, D; Li, W; Massetto, B; Mo, H; Rao, H; Stamm, LM; Wei, L; Xie, Q | 1 |
| Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q | 1 |
| Bixby, AL; Fitzgerald, L; Leek, R; Mellinger, J; Sharma, P; Tischer, S | 1 |
| Campise, M; D'Ambrosio, R; Franchina, M; Lampertico, P; Messa, P; Parlati, L; Pasulo, L; Pol, S; Vinci, M; Zaltron, S | 1 |
| Baden, LR; Camp, PC; Chen, K; Coppolino, A; Fanikos, J; Givertz, MM; Goldberg, HJ; Haddad, EA; Harrington, DP; Johnson, ME; Kusztos, AE; Mallidi, HR; Mehra, MR; Singh, SK; Woolley, AE | 1 |
| Douglas, MW; Eden, JS; George, J; Tay, ES | 1 |
| Chen, M; Hu, P; Liu, K; Pan, Z; Peng, M; Qiu, K; Ren, H; Shen, Y; Xue, W | 1 |
| Aghemo, A; Parigi, TL; Torres, MCP | 1 |
| Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M | 1 |
| Barreca, GS; Casalinuovo, F; Costa, C; Giancotti, A; Greco, G; Liberto, MC; Marascio, N; Matera, G; Mazzitelli, M; Pavia, G; Pisani, V; Serapide, F; Torti, C; Trecarichi, EM | 1 |
| Brandão-Mello, CE; Costa, VD; de Souza Rodrigues, LLLX; do Amaral Mello, FC; Dos Santos Silva, PGC; Lampe, E; Nunes, EP | 1 |
| Buggisch, P; Klinker, H; Lonjon-Domanec, I; Mauss, S; Müller, T; Nalpas, C; Pathil-Warth, A; Sarrazin, C; Schlag, M; Simon, KG; Wegner, S; Zimmermann, T | 1 |
| Agostinacchio, E; Carraturo, I; Cela, M; Chimenti, A; Copetti, M; Cuccorese, G; De Gioia, S; Giannelli, A; Lauletta, G; Losappio, R; Mangia, A; Mazzola, M; Mennea, G; Metrangolo, A; Minerva, N; Napoli, N; Palmieri, V; Piazzolla, V; Piccigallo, E; Potenza, D; Sabbà, C; Santoro, R; Tagarielli, V; Visaggi, E | 1 |
| Bianchi, L; Campione, E; Dattola, A; Di Paolo, D; Di Prete, M; Ferlosio, A; Orlandi, A | 1 |
| Behar, E; Coffin, PO; Fox, R; Hern, J; Kinnard, EN; Matheson, T; Page, K; Santos, GM; Silvis, J; Vittinghoff, E; Walker, J | 1 |
| Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X | 1 |
| Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V | 1 |
| Asensi-Diez, R; Del Rio-Valencia, JC; Muñoz-Castillo, I; Tamayo-Bermejo, R | 1 |
| Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R | 1 |
| Aizaki, H; Hatanaka, T; Hmwe, SS; Hoshino, T; Kakizaki, S; Naganuma, A; Sato, K; Tateyama, Y; Uraoka, T; Wakita, T; Yoshinari, F | 1 |
| Kanda, T; Kaneko, T; Komoriya, T; Kuroda, K; Matsumoto, N; Matsuoka, S; Moriyama, M; Nakajima, N; Nirei, K; Ogawa, M; Shibata, T; Takayama, T; Tamura, A; Yamamoto, T; Yamazaki, M | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Wu, SH | 1 |
| Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ | 1 |
| Alavi, M; Dore, GJ; Grebely, J; Hajarizadeh, B; Kaveh-Ei, S; Malekzadeh, R; Merat, S; Poustchi, H; Rahimi-Movaghar, A; Shadloo, B | 1 |
| Eisenberger, U; Friebus-Kardash, J; Gäckler, A; Herzer, K; Kribben, A; Treckmann, J; Wedemeyer, H; Witzke, O | 1 |
| Wahid, B | 1 |
| Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
| Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A | 1 |
| Bruckert, E; Caron, J; Dubart-Kupperschmitt, A; Fourrier, A; Gómez-Lechón, MJ; Heslan, JM; Luce, E; Nguyen, TH; Pène, V; Rosenberg, AR; Saheb, S; Tolosa, L; Villaret, M; Weber, A | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP | 1 |
| Mole, B | 1 |
| Dalzell, MD | 1 |
| Tse, MT | 1 |
| Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I | 1 |
| Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X | 1 |
| Berrey, MM; Cornpropst, MT; Denning, J; Gao, B; Lawitz, EJ; Mathias, A; Mo, H; Rodriguez-Torres, M; Symonds, WT | 1 |
| Flisiak, R; Jaroszewicz, J; Parfieniuk-Kowerda, A | 1 |
| Berg, T; Forns, X; Mariño, Z; van Bömmel, F | 1 |
| Ding, X; Gane, EJ; Hyland, RH; McHutchison, JG; Pang, PS; Stedman, CA; Subramanian, GM; Svarovskaia, E; Symonds, WT | 1 |
| Asselah, T | 1 |
| Cohen, J | 2 |
| Corouge, M; Pol, S; Vallet-Pichard, A | 1 |
| Boccaccio, V; Bruno, S | 1 |
| Dieterich, DT; Martel-Laferrière, V | 2 |
| Asselah, T; Marcellin, P | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Sheridan, C | 1 |
| Denning, J; Guedj, J; Lawitz, E; Pang, PS; Perelson, AS; Rodriguez-Torres, M; Symonds, W | 1 |
| Fralick, M | 1 |
| Chung, RT; deLemos, AS | 1 |
| Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N | 1 |
| Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Watts, G | 1 |
| Callaway, E | 1 |
| Feld, JJ | 1 |
| Chan, J | 1 |
| Adler, H; Lambert, JS | 1 |
| Rice, CM; Saeed, M | 1 |
| Senior, M | 1 |
| Slomski, A | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Henry, L; Lam, B; Younossi, Z | 1 |
| Burki, T | 1 |
| Chung, RT; Feeney, ER | 1 |
| Rolland, S; Vachon, ML | 1 |
| Cooke, G; Hill, A | 1 |
| Carroll, J | 2 |
| Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P | 1 |
| Brainard, D; Chodavarapu, K; Crespo Garcia, J; De Knegt, R; Doehle, B; Drenth, JP; Gontcharova, V; Hedskog, C; McHutchison, JG; Miller, MD; Mo, H; Stamm, LM; Svarovskaia, E | 1 |
| Borentain, P; Botta-Fridlund, D; Colson, P; Dhiver, C; Garcia, S; Gerolami, R; Gregoire, E; Hardwigsen, J | 1 |
| Donaldson, EF; Harrington, PR; Naeger, LK; O'Rear, JJ | 1 |
| Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F | 1 |
| Beavers, JW; Klibanov, OM; Summers, BB | 1 |
| Price, JC; Terrault, NA | 1 |
| Abd-Rabou, AA; Belousova, V; Mousa, SA | 1 |
| Wapner, J | 1 |
| Kuehn, BM | 1 |
| Cook, C; Phelan, M | 1 |
| Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA | 1 |
| Foster, GR | 1 |
| Chan, E; Gandhi, M; Lim, SG | 1 |
| Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA | 1 |
| Goozner, M | 1 |
| Beaumont, JL; Beckerich, F; Cordonnier, C; Gautier, E; Hézode, C; Maury, S; Robin, C | 1 |
| Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA | 1 |
| Alqahtani, SA; Dhingra, A; Kapoor, S | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Charlton, MR; Gallegos-Orozco, JF | 1 |
| Aghemo, A; Donato, MF | 1 |
| Adhoute, X; Ansaldi, C; Bourlière, M; Castellani, P; Oules, V | 1 |
| Baiguera, C; Panzeri, C; Puoti, M; Rossotti, R | 1 |
| Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS | 1 |
| Schwartz, M | 1 |
| Serfaty, L | 1 |
| Childs-Kean, LM; Hand, EO | 1 |
| Bennett, M; Bernstein, D; Cooper, JN; Freilich, BF; Ghalib, R; Gitlin, N; Harlan, W; Hawkins, T; Hennicken, D; Hughes, EA; Kowdley, KV; Lalezari, JP; Lawitz, E; McPhee, F; Nelson, DR; Oguchi, G; Ortiz-Lasanta, G; Pockros, PJ; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Thuluvath, PJ; Varunok, P; Younes, ZH | 1 |
| Carey, L | 1 |
| Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M | 1 |
| Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Bartlett, C; Griffin, S; Harris, M; Ross-Thriepland, D; Shaw, J; Stewart, H | 1 |
| Hayward, P | 1 |
| Manns, MP; Wedemeyer, H; Zeuzem, S | 1 |
| Avalos, D; Bhamidimarri, KR; Carrion, AF; Gutierrez, JA; Martin, P; O'Brien, C; Peyton, A | 1 |
| Brault, P; Klotz, C; Mallet, V; Pol, S; Sultanik, P | 1 |
| Chu, EY; McCausland, D; Simpson, CL | 1 |
| Besur, SV; deLemos, AS; Noell, BC | 1 |
| Bagcchi, S | 1 |
| Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B | 1 |
| Fazel, Y; Golabi, P; Lam, B; Younossi, Z | 1 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Ryoo, JY; Yang, HJ; Yoo, BK | 1 |
| Bonacci, M; Campistol, JM; Esforzado, N; Forns, X; Londoño, MC; Sotoca, JM | 1 |
| Baldelli, S; Cattaneo, D; Gervasoni, C; Milazzo, L; Peri, AM; Rizzardini, G | 1 |
| Ahmed, A; Daugherty, TJ; Higgins, JP; Perumpail, RB; Pham, EA; Wong, RJ | 1 |
| Adam, P; Bhamidimarri, KR; Christopher, O; Cynthia, L; Czul, F; David, R; Eugene, S; Frank, C; Hernandez, M; Jeffers, L; Kalyan Ram, B; Lennox, J; Levy, C; Maria, H; Martin, P; O'Brien, C; Paul, M; Peyton, A; Roth, D; Schiff, E | 1 |
| Aqel, BA; Chervenak, AE; Keaveny, AP; Leise, M; McLemore, R; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Kmietowicz, Z | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 2 |
| Dusheiko, G; Kalafateli, M; Manousou, P | 1 |
| Gori, A; Grossi, PA; Marigliano, A; Menzo, S; Tavio, M; Vivarelli, M | 1 |
| McCarthy, M | 1 |
| Berg, T; Manns, MP; Zeuzem, S | 1 |
| Giard, JM; Terrault, NA | 1 |
| Forns, X; Gambato, M; Lens, S; Mariño, Z | 1 |
| Brainard, D; Dieterich, D; Esteban, R; Gane, E; Jacobson, IM; Lawitz, E; McHutchison, JG; McNally, J; Nelson, DR; Sulkowski, MS; Symonds, WT; Zeuzem, S | 1 |
| Bhamidimarri, KR; Carrion, A; Gutierrez, JA; Peyton, AL | 1 |
| Klibanov, OM; Lomberk, M | 1 |
| Barnard, GF; Barry, C; Bozorgzadeh, A; Mehta, S; Punzalan, CS; Rodrigues, J; Zacharias, I | 1 |
| Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J | 1 |
| Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Beckebaum, S; Bester, C; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL; Stahl, M; Vorona, E | 1 |
| Anderson, PL; Bushman, LR; Chen, X; Hodara, A; Jimmerson, LC; Kiser, JJ; Rower, JE; Zheng, JH | 1 |
| Debes, JD; Ricci, P | 1 |
| Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM | 1 |
| Cheung, EJ; English, JC; Jedrych, JJ | 1 |
| Costilla, V; Gutierrez, JA; Mathur, N | 1 |
| Wyles, DL | 1 |
| Gibson, W; Klibanov, OM; Mullins, C | 1 |
| Jordan, S; Lang, M; Lohse, AW; Nashan, B; Pischke, S; Polywka, S; Proske, VM; Sterneck, M | 1 |
| Mohammad, RA; Regal, RE; Smith, MA | 1 |
| Brown, RS; Darling, JM; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Jacobson, IM; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Reddy, KR; Stewart, TG; Sulkowski, MS; Vargas, HE | 1 |
| Brainard, DM; Chan, HL; Han, LL; Knox, SJ; Lai, CL; Mo, H; Wong, VW; Yang, JC; Yuen, MF | 1 |
| Brown, RS; Burton, JR; Di Bisceglie, AM; Durand, C; Frenette, CT; Fried, MW; Kuo, A; Kwo, P; Morelli, GJ; Nelson, DR; O'Leary, JG; Reddy, KR; Stewart, TG; Stravitz, RT; Terrault, NA | 1 |
| Ryder, SD; Thiagarajan, P | 1 |
| Alric, L; Cacoub, P; Costopoulos, M; Fontaine, H; Guillaud, C; Hezode, C; Izzedine, H; Le Garff-Tavernier, M; Mallet, M; Musset, L; Plaisier, A; Pol, S; Poynard, T; Saadoun, D; Si Ahmed, SN; Thibault, V | 1 |
| Alric, L; Barange, K; Cointault, O; Del Bello, A; Esposito, L; Izopet, J; Kamar, N; Lavayssière, L; Marion, O; Métivier, S; Ribes, D; Rostaing, L | 1 |
| Abbott, S; Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Jolley, TA; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McLaughlin, M; Meissner, EG; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Proschan, M; Seamon, C; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E | 1 |
| Adhoute, X; Ansaldi, C; Benali, S; Bourlière, M; Castellani, P; Halfon, P; Oules, V; Portal, I | 1 |
| Brainard, DM; Doehle, B; Dvory-Sobol, H; Gane, E; Hedskog, C; Jacobson, IM; Lawitz, E; Martin, R; McHutchison, JG; Miller, MD; Mo, H; Nelson, DR; Svarovskaia, ES | 1 |
| Alao, O; Anastos, K; Brennan-Ing, M; Ernst, J; Karpiak, SE; Kuniholm, MH; Leach, T; Lunievicz, J; Nash, D; Olivo, N; Vazquez, Y | 1 |
| Dominguez-Dominguez, L; Jarrin-Estupiñan, ME; Kessler-Saiz, P; Marchan-Lopez, A | 1 |
| Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X | 1 |
| Abecassis, MM; Brooks, H; Grant, JL; Hawkins, C; Koppe, SW; Palella, FJ; Stosor, V | 1 |
| Dallas, MH; Santiago, T; Thomas, P | 1 |
| Chen, TM; Huang, PT; Li, YC | 1 |
| Gonzalez, HC; Nair, S; Satapathy, SK | 1 |
| Li, CX; Li, W; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Pinchera, B; Scotto, R; Zappulo, E | 1 |
| Berkowitz, L; Bichoupan, K; Branch, AD; Cha, A; Del Bello, D; Dieterich, DT; Doyle, E; Fierer, DS; Gardenier, D; Harty, A; Levine, C; Ng, M; Odin, J; Patel, N; Perumalswami, PV; Schiano, TD; Sorbera, M | 1 |
| Aljudaibi, B; Bilodeau, M; Congly, SE; Cooper, C; Faisal, N; Ghali, MP; Hirsch, G; Hussaini, T; Leonard, J; Lilly, LB; Ma, MM; Peltekian, K; Renner, EL; Yoshida, EM | 1 |
| Agarwal, K; Feld, J; Henry, L; Hezode, C; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Diefenbach, CS; Hymes, KB; Lin, RJ; Moskovits, T | 1 |
| Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R | 1 |
| Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H | 1 |
| Park, SH | 1 |
| Jung, YK | 1 |
| Chandrasekar, PH; Surapaneni, M; Wahba, MR | 1 |
| Alkhouri, N; Apfel, T; Hanouneh, IA; Hanouneh, M; Jackson, WE; John, BV; Zein, NN; Zervos, X | 1 |
| Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M | 1 |
| Bremer, B; Cloherty, G; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Lehmann, P; Maasoumy, B; Manns, MP; Pawlotsky, JM; Perner, D; Reinhardt, B; Sarrazin, C; Vermehren, J; Wedemeyer, H; Welker, MW; Zeuzem, S | 1 |
| Alshatti, F; Hull, MW; Moosavi, S; Yoshida, EM | 1 |
| Chodavarapu, K; McNally, J; Moreno, C; Schreiber, J; Svarovskaia, E | 1 |
| Tseng, A; Wong, DK | 1 |
| Amblard, F; Amiralaei, S; Cho, JH; Coats, SJ; Domaoal, RA; Ehteshami, M; Khalil, A; Lee, SS; Lin, B; Lu, X; Ozturk, T; Schinazi, RF; Shelton, JR; Stanton, RA; Suesserman, JE; Tao, S; Whitaker, T; Zhang, H; Zhou, L | 1 |
| Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y | 1 |
| Beyer, P; de Joncheere, K; Hill, S; Iyengar, S; Tay-Teo, K; Vogler, S; Wiktor, S | 1 |
| Abergel, A; Anty, R; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; de Ledinghen, V; Debette-Gratien, M; Di Martino, V; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rohel, A; Roque-Afonso, AM; Rossignol, E; Samuel, D; Silvain, C | 1 |
| Silverman, E | 1 |
| Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI | 1 |
| Chen, GF; Chen, J; Cheng, J; Dou, XG; Du, N; Duan, ZP; Fan, JG; Fu, QC; Han, Y; Hou, JL; Ji, D; Jia, JD; Jia, ZS; Lau, G; Li, B; Li, F; Liu, JL; Lu, LG; Niu, XX; Ren, H; Shang, J; Shao, Q; Wang, C; Wang, GQ; Wang, JP; Wang, XJ; Wang, YD; Wei, L; Wong, A; Wu, V; Xie, Q; Yang, XX; Zhang, WH; Zhang, YX; Zhuang, H | 1 |
| Afdhal, NH; Brainard, DM; Chuang, SM; Ding, X; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Ma, J; McHutchison, JG; Miller, MD; Mo, H; Pang, PS; Sarrazin, C; Svarovskaia, ES | 1 |
| Ampuero, J; Reddy, KR; Romero-Gomez, M | 1 |
| Brügger, U; Girardin, F; Goossens, N; Negro, F; Perrier, A; Riguzzi, M; Vernaz, N | 1 |
| Alric, L; Aumaître, H; Bani-Sadr, F; Billaud, E; Bouchaud, O; Boué, F; Chas, J; Dabis, F; Dominguez, S; Esterle, L; Gervais, A; Gilbert, C; Goujard, C; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Morlat, P; Neau, D; Piroth, L; Poizot-Martin, I; Rosenthal, E; Salmon, D; Simon, A; Sogni, P; Valantin, MA; Vittecoq, D; Wittkop, L; Zucman, D | 1 |
| Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A | 1 |
| Amoroso, A; Arese, D; Cocchis, D; Dell Olio, D; Magistroni, P; Martini, S; Mirabella, S; Moschini, P; Ottobrelli, A; Rizza, G; Rizzetto, M; Romagnoli, R; Sacco, M; Salizzoni, M; Saracco, GM; Stradella, D; Strona, S; Tandoi, F | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A | 1 |
| Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O | 1 |
| An, D; Brainard, D; Gane, EJ; Hyland, RH; McHutchison, JG; Svarovskaia, ES | 1 |
| Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R | 1 |
| Agüero, F; Ambrosioni, J; Costa, J; Forner, A; Laguno, M; Lligoña, A; Londoño, MC; Manzardo, C; Miró, JM; Moreno, A; Rimola, A; Ruiz, P | 1 |
| Bobardt, M; Chatterji, U; Gallay, PA; Schaffer, L; Wood, M | 1 |
| Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S | 1 |
| Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H | 1 |
| D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M | 1 |
| Ahn, J; Badano, G; Chalkidou, K; Cubillos, L; Hauegen, RC; Henshall, C; Kieslich, K; Krubiner, CB; Littlejohns, P; Lu, L; Pearson, SD; Rid, A; Whitty, JA; Wilson, J | 1 |
| Gornall, J; Hoey, A; Ozieranski, P | 1 |
| Brainard, DM; Chuang, WL; Gane, E; Gao, B; Han, KH; Kao, JH; Sulkowski, MS; Yang, JC | 1 |
| Ahmed, A; Chang, CY; Daugherty, T; Doshi, D; Garcia, G; Gupta, S; Kumari, R; Lutchman, G; Nguyen, MH; Nguyen, NH | 1 |
| Iacob, G; McCann, J; Uzoigwe, CE | 1 |
| Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A | 1 |
| Chahine, EB; Hemstreet, BA; Sucher, AJ | 1 |
| Cardoso, H; Gaspar, R; Macedo, G; Silva, M | 1 |
| Fortune, BE; Lim, JK; McCarty, TR; Njei, B | 1 |
| Beckman, AL; Bilinski, A; Boyko, R; Bruce, RD; Camp, GM; Gonsalves, GS; Lim, JK; Wall, AT; Wang, EA | 1 |
| Cattaneo, A; Maciocco, G | 1 |
| Guo, Y; Li, T; Qu, Y; Sun, C; Wang, L; Yang, B; Ye, Q | 1 |
| Stafford, N | 1 |
| Berry, K; Green, PK; Ioannou, GN; Su, F | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Ardeshna, K; Maciocia, N; O'Brien, A | 1 |
| Xia, N; Zhao, Q | 1 |
| Cuenca-Lopez, F; Rivero, A; Rivero-Juárez, A | 1 |
| Moiseev, S; Mukhin, N; Novikov, P | 1 |
| Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K | 1 |
| Berry, K; Green, PK; Ioannou, GN; Su, F; Tsui, JI; Williams, EC | 1 |
| King, L; Roy, V | 1 |
| Mazzucato, M | 1 |
| Canbay, A; Gerken, G; Herzer, K; Paul, A; Timm, J; Treckmann, J; Willuweit, K | 1 |
| Botta-Fridlund, D; Hachicha, M | 1 |
| Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J | 1 |
| Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R | 1 |
| Heppt, F; Sticherling, M | 1 |
| Abravanel, F; Bramley, P; Campbell, JD; Dalton, HR; Donnelly, MC; Fraser, AR; Hayes, PC; Imlach, SN; Johannessen, I; Kamar, N; Petrik, J; Ramalingam, S; Simpson, KJ | 1 |
| Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M | 1 |
| King, L; Ozieranski, P | 1 |
| Klaus, G; Szucs, TD; Weiss, M | 1 |
| Liu, H; Yan, Y; Zhang, T | 1 |
| Acevedo, P; Bernal Blanco, G; Gentil Govantez, MA; Gonzalez Roncero, FM; Gonzalez-Corvillo, C; Perez Valdivia, MA; Sousa, JM; Suarez Benjumea, A; Suñer Poblet, M | 1 |
| Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S | 1 |
| Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S | 1 |
| Hernandez, D; McPhee, F; Zhou, N | 1 |
| Cornberg, M; Deterding, K; Gerken, G; Hardtke, S; Klinker, H; Koch, A; Manns, MP; Papkalla, A; Pathil, A; Schott, E; Schulze Zur Wiesch, J; Spengler, U; Spinner, CD; Umgelter, A; von der Leyen, H; von Witzendorff, D; Weber, K; Wedemeyer, H; Welzel, TM; Wiegand, J; Zeuzem, S; Zöllner, C | 1 |
| Martin, SI; Pope-Harman, A; Pouch, S; Theodoropoulos, N; Whitson, BA | 1 |
| Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P | 1 |
| Allerton, M; Lai, JB; Pauly, MP; Ready, J; Seo, S; Witt, DJ; Witt, MA | 1 |
| Huang, J; Liao, H; Tan, P; Yan, X; Zhu, Z | 1 |
| Brandão-Mello, CE; Lampe, E; Peres-da-Silva, A | 1 |
| Chen, YS; Kao, JH; Liu, CH; Wang, SS | 1 |
| Yu, ML | 1 |
| Boucher, E; Chapman, W; Cheslock, P; Chung, RT; Curry, MP; Mantry, P; Molrine, DC; Schiano, TD; Smith, HL; Wang, Y | 1 |
| Booth, M | 1 |
| Brieva, T; Rivero, A; Rivero-Juarez, A | 1 |
| Barbati, ZR; Dieterich, DT; El Sayed, A; Fierer, DS; Foster, AL; Morey, T; Turner, SS | 1 |
| Jansen, JW; Linneman, TW; Powderly, GM | 1 |
| Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Lim, SG | 1 |
| Barauskas, O; Doehle, B; Dvory-Sobol, H; Feng, J; Han, B; Miller, MD; Mo, H; Perry, J; Rajyaguru, S; Svarovskaia, ES; Xu, S | 1 |
| Ammassari, A; Antinori, A; Fabbri, G; Grisetti, S; Mastrorosa, I; Mazzotta, V; Pinnetti, C; Vergori, A; Zaccarelli, M | 1 |
| Aziz, T; Hanif, FM; Laeeq, SM; Luck, NH; Mandhwani, RK; Mehdi, SH | 1 |
| Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B | 1 |
| Alric, L; Bellier, B; Cacoub, P; Comarmond, C; Costopoulos, M; Desbois, AC; Fontaine, H; Garrido, M; Klatzmann, D; Le Garff-Tavernier, M; Maciejewski, A; Musset, L; Pol, S; Poynard, T; Rosenzwajg, M; Saadoun, D; Si Ahmed, SN | 1 |
| Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN | 1 |
| Lawitz, EJ; Membreno, FE | 1 |
| Rachakonda, S; Reddy, PG; Ross, BS; Sofia, MJ; Zhang, HR | 1 |
| Bao, D; Chang, W; Chun, BK; Du, J; Espiritu, CL; Furman, PA; Jiang, Y; Keilman, M; Ross, BS; Sofia, MJ; Steuer, HM; Zhang, HR | 1 |
| Chee, GM; Poordad, F | 1 |
| Pockros, PJ | 1 |
| Desoky, OS; Elfiky, AA; Elshemey, WM; Gawad, WA | 1 |
93 review(s) available for sofosbuvir and Hepatitis C
| Article | Year |
|---|---|
Hepatitis C - New drugs and treatment prospects.
Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Structure; Molecular Targeted Therapy; Protease Inhibitors | 2019 |
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Road to elimination of HCV: Clinical challenges in HCV management.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Homosexuality, Male; Humans; Male; Sex Workers; Sexual and Gender Minorities; Sofosbuvir | 2022 |
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Sofosbuvir | 2022 |
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Quinoxalines; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response | 2022 |
Treatment of hepatitis C in children and adolescents: how far have we reached?
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome | 2023 |
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Hyperglycemia; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2023 |
Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Overview of hepatitis C infection, molecular biology, and new treatment.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2020 |
Direct-Acting Antiretroviral Therapy in Renal Transplant Recipients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Report of Our Experience and Literature Review.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization | 2020 |
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis.
Topics: Antiviral Agents; Hepatitis C; Humans; Kidney Failure, Chronic; Sofosbuvir | 2020 |
Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2020 |
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Sofosbuvir; Treatment Outcome | 2021 |
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
Topics: Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Osteosclerosis; Pyrrolidines; Sofosbuvir; Valine | 2021 |
Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic; Sofosbuvir; United States | 2022 |
Breakthroughs and challenges in the management of pediatric viral hepatitis.
Topics: Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2021 |
Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Users; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Sustained Virologic Response | 2021 |
Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome | 2017 |
Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Hepatitis C; Humans; Randomized Controlled Trials as Topic; Sofosbuvir | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors.
Topics: Acute Kidney Injury; Antiviral Agents; Drug Monitoring; Hepatitis C; Humans; Incidence; Kidney Diseases; Kidney Function Tests; Risk Factors; Sofosbuvir; Time Factors | 2018 |
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2018 |
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Economics, Medical; France; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Therapies, Investigational; Valine | 2019 |
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.
Topics: Administration, Oral; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Emerging treatments for hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2013 |
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Prodrugs; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Sofosbuvir for the treatment of hepatitis C virus.
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Hepacivirus; Hepatitis C; Sofosbuvir; Uridine Monophosphate; Virus Physiological Phenomena | 2014 |
Treatment of hepatitis C virus genotype 3-infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins | 2014 |
Management of HCV patients with cirrhosis with direct acting antivirals.
Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C treatment: an incipient therapeutic revolution.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
Interferon-free strategies with a nucleoside/nucleotide analogue.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Design; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Targeted Therapy; Nucleosides; Nucleotides; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Hepatitis C.
Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2014 |
Daclatasvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Antiviral treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Recent advances and future directions in the management of hepatitis C infections.
Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uridine Monophosphate | 2015 |
Recent advances in the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
Sofosbuvir as backbone of interferon free treatments.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis D, Chronic; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Changing the face of hepatitis C management - the design and development of sofosbuvir.
Topics: Antiviral Agents; Drug Combinations; Drug Design; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Hepatitis C; Humans; Sofosbuvir; Viral Load | 2015 |
Advances in hepatitis C therapies.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Transplantation; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2015 |
Development of sofosbuvir for the treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Drug Discovery; Hepacivirus; Hepatitis C; Humans; Sofosbuvir | 2015 |
Daclatasvir (Daklinza) for HCV genotype 3 infection.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2015 |
Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Recurrence; Retreatment; RNA, Viral; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Regimens for Patients Coinfected with Human Immunodeficiency Virus.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins | 2015 |
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Nausea; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2016 |
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Design; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir | 2015 |
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigational; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Quinoxalines; Sofosbuvir; Sulfonamides | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Quinoxalines; Republic of Korea; Sofosbuvir; Sulfonamides | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Republic of Korea; Ribavirin; Sofosbuvir | 2016 |
Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; RNA, Viral; Sexually Transmitted Diseases, Viral; Sofosbuvir; Transaminases; Transplant Recipients; Treatment Outcome | 2016 |
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Odds Ratio; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Valine | 2016 |
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.
Topics: Antiviral Agents; Databases, Bibliographic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Patient Compliance; Recurrence; Sofosbuvir; Treatment Outcome | 2017 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Tissue Donors; Viral Load | 2017 |
Hepatitis C virus genotype 4: Genotype 1's little brother.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Middle Aged; Sofosbuvir | 2017 |
The HCV NS5B nucleoside and non-nucleoside inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Guanosine Monophosphate; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2011 |
Interferon free hepatitis C treatment regimens: the beginning of another era.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2012 |
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
Nucleoside/nucleotide analogue polymerase inhibitors in development.
Topics: Cytidine; Deoxycytidine; Drugs, Investigational; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Protein Conformation; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
71 trial(s) available for sofosbuvir and Hepatitis C
| Article | Year |
|---|---|
Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Pharmaceutical Preparations; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome | 2022 |
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
Topics: Adolescent; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; RNA; Sofosbuvir; Treatment Outcome; United States | 2022 |
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use.
Topics: Dried Blood Spot Testing; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polyphosphates; Sofosbuvir | 2022 |
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2022 |
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
Topics: Antiviral Agents; Drug Users; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Substance Abuse, Intravenous | 2022 |
Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; RNA, Viral; Sofosbuvir; Viremia | 2023 |
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Treatment Outcome | 2023 |
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
Topics: Adolescent; Adult; Antiviral Agents; Equivalence Trials as Topic; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome | 2023 |
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Republic of Korea; Sofosbuvir; Treatment Outcome | 2023 |
Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2023 |
Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; RNA; Sofosbuvir; Treatment Outcome | 2023 |
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir | 2020 |
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inflammation; Insulin Resistance; Interleukin-1beta; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam | 2020 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Outcome Assessment, Health Care; Pharmacists; Pyrrolidines; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2020 |
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; New Zealand; Non-Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Ribavirin; Safety; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Comparing direct acting antivirals for hepatitis C using observational data - Why and how?
Topics: Antiviral Agents; Bayes Theorem; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Propensity Score; Sofosbuvir; Treatment Failure | 2020 |
Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Pregnancy; Pregnant Women; Sofosbuvir; Treatment Outcome | 2020 |
Novel combined single dose anti-hepatitis C therapy: a pilot study.
Topics: Adult; Antiviral Agents; Catechin; Female; Genotype; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Ribavirin; Sofosbuvir | 2021 |
Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kentucky; Pregnancy; Sofosbuvir; Treatment Outcome | 2021 |
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Topics: Adult; Antiviral Agents; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Sofosbuvir; United States | 2017 |
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Administration Schedule; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir | 2017 |
Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; Cohort Studies; Coinfection; Drug Combinations; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Sofosbuvir | 2017 |
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2017 |
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2018 |
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferon Type I; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Liver; Male; Mass Spectrometry; Middle Aged; Ribavirin; Sofosbuvir | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Graft Rejection; Graft Survival; Hepatitis C; Humans; Imidazoles; Kidney; Kidney Transplantation; Male; Middle Aged; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Tissue Donors; Treatment Outcome | 2018 |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2018 |
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult | 2018 |
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Topics: Alkynes; Antiviral Agents; Benzimidazoles; Benzoxazines; Black or African American; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Fluorenes; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Recurrence; Sofosbuvir | 2018 |
Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.
Topics: Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Genotype; Hepatitis C; Humans; Interleukins; Liver; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2018 |
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult | 2018 |
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Russia; Sofosbuvir; Sweden; Young Adult | 2019 |
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
Topics: Adult; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2019 |
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Heart Transplantation; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Transplantation; Male; Middle Aged; Pilot Projects; RNA, Viral; Sofosbuvir; Tissue Donors | 2019 |
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Topics: Aged; Brazil; Carbamates; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Mutation; Pyrrolidines; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2019 |
Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
Topics: Adult; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; Middle Aged; Prevalence; San Francisco; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2019 |
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2019 |
An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Ill-Housed Persons; Imidazoles; Iran; Male; Middle Aged; Prevalence; Pyrrolidines; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2019 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2013 |
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2013 |
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Fatigue; Female; Fluorenes; Furans; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Middle Aged; Nausea; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Topics: Adult; Antiviral Agents; Cyclic P-Oxides; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Nucleosides; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists | 2015 |
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2015 |
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Uridine Monophosphate; Valine; Young Adult | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
Topics: Allografts; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Simeprevir; Sofosbuvir | 2015 |
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hong Kong; Humans; Male; Middle Aged; Ribavirin; RNA; Sofosbuvir; Treatment Outcome | 2016 |
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis | 2016 |
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Furans; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinolines; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Viral Load | 2015 |
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Patient Reported Outcome Measures; Quality of Life; Ribavirin; Sofosbuvir | 2016 |
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2016 |
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2016 |
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Virus Activation | 2016 |
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir | 2017 |
492 other study(ies) available for sofosbuvir and Hepatitis C
| Article | Year |
|---|---|
Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.
Topics: Alanine; Animals; Antiviral Agents; Cell Line, Tumor; Dogs; Hepacivirus; Hepatitis C; Humans; Nucleic Acid Synthesis Inhibitors; Phosphoramides; Prodrugs; Replicon; Uracil Nucleotides; Uridine; Viral Nonstructural Proteins | 2019 |
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
Topics: Antiviral Agents; Cell Line; Deoxyadenosines; Deoxyribonucleosides; Halogenation; Hepacivirus; Hepatitis C; Humans; Structure-Activity Relationship | 2014 |
Synthesis and biological evaluation of a novel β-D-2'-deoxy-2'-α-fluoro-2'-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C; Humans; Liver; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Organophosphorus Compounds; Prodrugs; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Uridine; Virus Replication | 2018 |
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult | 2021 |
Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Registries; Sofosbuvir; Sustained Virologic Response; United States; Veterans | 2021 |
Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.
Topics: Chemokine CCL4; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukin-12 Subunit p40; Sofosbuvir; Treatment Outcome | 2021 |
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2021 |
Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.
Topics: Antiviral Agents; Burkina Faso; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Seroepidemiologic Studies; Sofosbuvir; Treatment Outcome; Viral Load | 2022 |
Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iran; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience.
Topics: Antiviral Agents; Coinfection; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Sofosbuvir; Treatment Outcome | 2022 |
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Replicon; Sofosbuvir | 2022 |
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Taiwan | 2022 |
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine.
Topics: Adolescent; Antiviral Agents; Child; Cohort Studies; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir; Treatment Outcome; Ukraine | 2022 |
Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iron; Lipids; Sofosbuvir | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
Drug delivery of sofosbuvir drug capsulated with the β-cyclodextrin basket loaded on chitosan nanoparticle surface for anti-hepatitis C virus (HCV).
Topics: Animals; Antiviral Agents; beta-Cyclodextrins; Chitosan; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Mice; Nanoparticles; Pharmaceutical Preparations; Sofosbuvir; Treatment Outcome | 2022 |
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; COVID-19 Drug Treatment; Disease Progression; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Treatment Outcome | 2022 |
Case study of hepatitis C virus control in Egypt: impact of access program.
Topics: Egypt; Hepacivirus; Hepatitis C; Humans; Prevalence; Sofosbuvir | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.
Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Republic of Korea; RNA; Sofosbuvir; Treatment Outcome | 2022 |
Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Pancreatitis; Pantoprazole; Sofosbuvir | 2022 |
Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iran; Liver Cirrhosis; Sofosbuvir; Treatment Outcome | 2022 |
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Stress Disorders, Post-Traumatic; Sustained Virologic Response; Treatment Outcome; Veterans | 2022 |
In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS.
Topics: Animals; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Male; Rats; Silymarin; Sofosbuvir; Tandem Mass Spectrometry | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Viremia | 2022 |
RNA-Dependent RNA Polymerase of the Second Human Pegivirus Exhibits a High-Fidelity Feature.
Topics: Antiviral Agents; Coinfection; Flaviviridae Infections; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Nucleosides; Pegivirus; Phylogeny; RNA Viruses; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir | 2022 |
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry.
Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Patient Reported Outcome Measures; Quality of Life; Registries; Sofosbuvir | 2022 |
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort.
Topics: Aged; Antiviral Agents; Brazil; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |
Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study.
Topics: Antiviral Agents; beta-Thalassemia; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iron Overload; Male; Pyrrolidines; Sofosbuvir; Treatment Outcome | 2022 |
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Hepacivirus; Hepatitis C; Humans; Lung; Nucleosides; SARS-CoV-2; Sofosbuvir | 2022 |
Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Sofosbuvir | 2023 |
Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Prospective Studies; Sofosbuvir; Tenofovir | 2023 |
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Mental Disorders; Sofosbuvir | 2022 |
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir | 2023 |
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir | 2022 |
Treatment-experienced patient with Roux-en-Y gastric bypass successfully treated with sofosbuvir/velpatasvir/voxilaprevir: A case report.
Topics: Antiviral Agents; Gastric Bypass; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2023 |
Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Romania; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
Topics: Drug Costs; Health Expenditures; Hepatitis C; Humans; Medication Adherence; Retrospective Studies; Sofosbuvir | 2023 |
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
Topics: Antiviral Agents; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Treatment Failure | 2023 |
Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lost to Follow-Up; Sofosbuvir | 2023 |
A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.
Topics: Drug Users; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Seroepidemiologic Studies; Sofosbuvir; South Africa; Substance Abuse, Intravenous | 2023 |
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2023 |
Visual symptoms with Sofosbuvir in hepatitis C treatment - a case report from Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pakistan; Sofosbuvir; Treatment Outcome | 2023 |
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Malaysia; Sofosbuvir | 2023 |
Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Viral Nonstructural Proteins | 2023 |
Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Male; Pegivirus; Polyethylene Glycols; RNA, Viral; Sofosbuvir; Viremia | 2023 |
Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pancreas Transplantation; Pyrrolidines; Quinoxalines; Sofosbuvir; Treatment Failure | 2023 |
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study.
Topics: Antiviral Agents; Drug Therapy, Combination; Gastrointestinal Microbiome; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Prospective Studies; Sofosbuvir | 2023 |
Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Young Adult | 2023 |
Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
Topics: Antiviral Agents; Benzimidazoles; Genotype; Hepacivirus; Hepatitis C; Humans; Quinoxalines; Sofosbuvir; Sustained Virologic Response | 2023 |
The pre-conception maternal exposure to Sofosbuvir affects the mitochondrial biogenesis in prenatal fetal tissues: Experimental study on rats.
Topics: Animals; DNA, Mitochondrial; Female; Fetus; Genotype; Hepatitis C; Humans; Male; Maternal Exposure; Organelle Biogenesis; Placenta; Pregnancy; Rats; Sofosbuvir | 2023 |
Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prisons; Retrospective Studies; Sofosbuvir; Taiwan; Treatment Outcome | 2023 |
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2023 |
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Spectroscopic study to verify the anti-hepatitis C virus (HCV) treatment through a delivery system of the sofosbuvir drug on chitosan and pycnogenol nanoparticles surface.
Topics: Animals; Antiviral Agents; Chitosan; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Mice; Pharmaceutical Preparations; Ribavirin; Sofosbuvir; Spectrum Analysis | 2023 |
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Sofosbuvir; Treatment Outcome | 2023 |
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats.
Topics: Animals; Antioxidants; Antiviral Agents; Carbon Tetrachloride; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Interleukin-6; Liver Cirrhosis; NF-kappa B; Rats; Sofosbuvir | 2023 |
Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct acting anti-virals, but salvage therapy may be life-saving.
Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Salvage Therapy; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Efficacy and Safety of Directly Acting Antivirals in Patients with Hepatitis C Infection on Hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; India; Prospective Studies; Renal Dialysis; Sofosbuvir; Treatment Outcome | 2023 |
Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Retrospective Studies; Salvage Therapy; Sofosbuvir | 2023 |
Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Subgenomic RNA | 2023 |
The Intergeneration Long-Lasting Consequences of Pre-Conceptional Exposure to Sofosbuvir on the Ovarian Tissues of F1 Offspring: Experimental Study on Rats.
Topics: Animals; Cell Communication; Female; Fertilization; Hepatitis C; Humans; Male; Pregnancy; Rats; Reproduction; Sofosbuvir | 2023 |
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.
Topics: Analgesics, Opioid; Antiviral Agents; Fentanyl; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Hydrocodone; Oxycodone; Sofosbuvir | 2023 |
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Direct-Acting Antiviral Drug Modulates the Mitochondrial Biogenesis in Different Tissues of Young Female Rats.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Organelle Biogenesis; Rats; Rats, Wistar; Sofosbuvir; Treatment Outcome | 2023 |
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome | 2023 |
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome | 2023 |
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Heart Transplantation; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Diseases; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Uridine Monophosphate | 2020 |
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; Markov Chains; Quality-Adjusted Life Years; Sofosbuvir; Universal Health Insurance | 2019 |
Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.
Topics: Antiviral Agents; Child; Child, Preschool; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Hepatitis C; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Viral Load | 2019 |
Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Topics: Adult; Aged; Antiviral Agents; Bangladesh; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Pyrrolidines; RNA, Viral; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2019 |
Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Pakistan; Prevalence; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2019 |
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
Topics: Adolescent; Adult; Antiviral Agents; Georgia; Georgia (Republic); Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response | 2020 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2019 |
Access to Direct-Acting Antiviral Treatment for Hepatitis C Virus Among Veterans With Serious Mental Illness.
Topics: Adult; Aged; Antiviral Agents; Female; Health Services Accessibility; Hepatitis C; Humans; Logistic Models; Male; Mental Disorders; Middle Aged; Sofosbuvir; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans | 2020 |
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carbamates; Female; Hepatitis C; Herpes Genitalis; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Sofosbuvir | 2019 |
CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
Topics: CCR5 Receptor Antagonists; Cell Line; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Maraviroc; Raltegravir Potassium; Receptors, CCR5; Sofosbuvir; Sulfoxides; Virus Replication | 2019 |
Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Scleroderma, Localized; Sofosbuvir; Thigh; Uridine Monophosphate | 2019 |
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mice; Sofosbuvir | 2020 |
Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.
Topics: Aged; Antiviral Agents; Anxiety; Benzimidazoles; Depression; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Psychological Tests; Quality of Life; Self Report; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
The paediatric population: the forgotten element to eliminating hepatitis C virus.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Chronic Disease; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infectious Disease Transmission, Vertical; Liver Diseases; Male; Prevalence; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult | 2020 |
Hepatitis C virus therapy in children: No one should be left behind.
Topics: Benzimidazoles; Child; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2020 |
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Pyrrolidines; Renal Dialysis; Renal Insufficiency; Safety; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy.
Topics: Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sofosbuvir; Waldenstrom Macroglobulinemia | 2020 |
A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Odds Ratio; Primary Health Care; Program Evaluation; Reward; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Living Donor Liver Transplantation From Hepatitis C-Infected Donor to Hepatitis C-Infected Recipient.
Topics: Adult; Antiviral Agents; Carbamates; Child; Fatty Liver; Female; Hepacivirus; Hepatectomy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Function Tests; Liver Neoplasms; Liver Transplantation; Living Donors; Monitoring, Physiologic; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2020 |
Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity.
Topics: Animals; Antiviral Agents; Cells, Cultured; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Hepatitis C; Hepatocytes; Humans; Male; Oxidative Stress; Primary Cell Culture; Rats; Sofosbuvir | 2020 |
Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
Topics: Antiviral Agents; Benzimidazoles; Black or African American; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; New Jersey; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2020 |
Universal Disease Screening and Treatment - The Egyptian Example.
Topics: Adolescent; Adult; Antiviral Agents; Egypt; Hepatitis C; Humans; Mass Screening; Sofosbuvir | 2020 |
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Monitoring; Female; Half-Life; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets | 2020 |
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Micellar high performance liquid chromatographic method for separation and validation of two anti-hepatitis C- virus drugs in pure form, human plasma and human urine.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Cost-Benefit Analysis; Hepatitis C; Humans; Limit of Detection; Reproducibility of Results; Ribavirin; Sofosbuvir; Solubility | 2020 |
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine | 2020 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult | 2020 |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir | 2020 |
HCV eradication in chronic kidney disease: ready for prime time?
Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir | 2020 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Epclusa Approved For Children With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Child; Drug Approval; Drug Combinations; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2020 |
Modeling based response guided therapy in subjects with recent hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis C; Humans; Male; Middle Aged; Models, Theoretical; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult | 2020 |
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia.
Topics: Adolescent; Adult; Antiviral Agents; Female; Genotype; Georgia (Republic); Health Services; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Ukrainian health authorities adopt hepatitis C project.
Topics: Antiviral Agents; Carbamates; Delivery of Health Care; Drug Therapy, Combination; Drugs, Generic; Health Plan Implementation; Hepacivirus; Hepatitis C; Humans; Imidazoles; Physicians; Pyrrolidines; Sofosbuvir; Ukraine; Valine | 2020 |
Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; HIV; Humans; Phylogeny; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Sulfonamides; Uracil; Viral Nonstructural Proteins | 2020 |
Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C.
Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome | 2020 |
Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir/velpatasvir combination.
Topics: Acute Disease; Adult; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2020 |
Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidines; Sofosbuvir; Uridine; Valine | 2020 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Topics: Balloon Occlusion; Carbamates; Female; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Middle Aged; Sofosbuvir; Treatment Outcome | 2020 |
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Romania; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2020 |
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Kidney Transplantation; Linear Models; Liver; Liver Transplantation; Male; Middle Aged; Proof of Concept Study; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load; Viremia | 2021 |
Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Myanmar; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Drug Discovery; Drug Repositioning; Exonucleases; Hepacivirus; Hepatitis C; Humans; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2020 |
Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation.
Topics: Antiviral Agents; Carbamates; Child; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Transplantation, Haploidentical; Treatment Outcome | 2021 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times.
Topics: Aged; Antibiotics, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Hepatitis C; Humans; Liver Neoplasms; Myanmar; Sofosbuvir; Treatment Outcome | 2021 |
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2021 |
Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
Topics: Alleles; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukins; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir | 2020 |
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Topics: Antiviral Agents; Brazil; Carbamates; Cell Line, Tumor; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Mutation; Pyrrolidines; Recurrence; Sofosbuvir; Valine; Viral Nonstructural Proteins; Virus Replication | 2021 |
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine | 2021 |
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Chromosomes, Artificial, Bacterial; COVID-19; COVID-19 Drug Treatment; HEK293 Cells; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Replicon; RNA-Binding Proteins; SARS-CoV-2; Sofosbuvir; Vero Cells; Virus Replication | 2021 |
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2021 |
Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Severity of Illness Index; Sofosbuvir; Survival Rate; Young Adult | 2020 |
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Outcome | 2021 |
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2021 |
Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
Topics: Antiviral Agents; Child; Coinfection; End Stage Liver Disease; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Prospective Studies; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Mass Screening; Pilot Projects; Renal Dialysis; Seroepidemiologic Studies; Sofosbuvir; Sustained Virologic Response; Taiwan; Uremia; Viremia | 2021 |
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Topics: Aged; Antiviral Agents; Drug Interactions; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Renal Dialysis; Sofosbuvir | 2021 |
Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Sofosbuvir | 2020 |
Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
Topics: Antiviral Agents; Central Nervous System Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2022 |
Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2021 |
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.
Topics: Antigens, Neoplasm; Antiviral Agents; Cell Adhesion Molecules; Cohort Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2022 |
Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Topics: Adolescent; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Child; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Sofosbuvir | 2021 |
Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
Topics: Cost-Benefit Analysis; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Sofosbuvir | 2021 |
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Muscle, Skeletal; Quality of Life; Sofosbuvir; Treatment Outcome | 2021 |
The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
Topics: Adult; Antiviral Agents; Benzimidazoles; British Columbia; Female; Fluorenes; Health Care Costs; Hepatitis C; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir | 2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Middle Aged; Registries; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Failure; Treatment Outcome | 2021 |
Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Topics: Adult; Antiviral Agents; Biomarkers; Blood Chemical Analysis; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Host Microbial Interactions; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Real-Time Polymerase Chain Reaction; RNA, Viral; ROC Curve; Sofosbuvir; Valine; Viral Load | 2021 |
Sofosbuvir in HCV patients with chronic kidney disease: No time for caution.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Mass Screening; Middle Aged; Pilot Projects; Program Evaluation; Public Health; Pyrrolidines; Rural Health Services; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2021 |
Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient.
Topics: Antiviral Agents; Benzimidazoles; Child; Female; Fluorenes; Gain of Function Mutation; Genotype; Hepatitis C; Humans; Sofosbuvir; STAT3 Transcription Factor | 2021 |
Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cells, Cultured; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lymphocytes; Male; Middle Aged; Myeloid Cells; Sofosbuvir; Viral Load | 2021 |
Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma.
Topics: Antiviral Agents; Capsules; Chromatography, Thin Layer; Densitometry; Hepatitis C; Humans; Limit of Detection; Simeprevir; Sofosbuvir | 2021 |
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
Topics: Benzimidazoles; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Valine | 2021 |
Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; World Health Organization | 2021 |
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Developing Countries; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult | 2021 |
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey | 2021 |
Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Lung Diseases, Interstitial; Sofosbuvir; Symptom Flare Up | 2021 |
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Retreatment; Sofosbuvir; Sustained Virologic Response | 2021 |
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance; Female; Hepatitis C; Humans; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Quinoxalines; RNA-Dependent RNA Polymerase; Sofosbuvir; Sulfonamides; United States; Viral Nonstructural Proteins | 2021 |
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
Topics: Adult; Antiviral Agents; Australia; Canada; Carbamates; Drug Combinations; Female; Germany; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Netherlands; New Zealand; Sofosbuvir; Switzerland; Time Factors; Treatment Outcome; United Kingdom | 2021 |
Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China.
Topics: Adult; Antiviral Agents; China; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Ribavirin; Rural Population; Sofosbuvir; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome | 2021 |
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.
Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Transplantation; Sofosbuvir | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cost of Illness; Disability Evaluation; Drugs, Generic; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; International Normalized Ratio; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Sofosbuvir; Young Adult | 2021 |
The Moral Necessity to Increase Access to HCV+ Transplants With Early Treatment for HCV-naive Patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Morals; Sofosbuvir; Transplants | 2022 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Carbamates; Creatinine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Nephritis, Interstitial; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Time Factors; Valine | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; Humans; Risk Factors; Sofosbuvir; Tachycardia, Ventricular | 2017 |
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Tenofovir; Treatment Outcome | 2017 |
Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
Topics: Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Sofosbuvir | 2017 |
Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lichen Planus; Lip; Lip Diseases; Male; Middle Aged; Ribavirin; Sofosbuvir | 2017 |
Mixed Essential Cryoglobulinemia.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Exanthema; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Immunologic Factors; Male; Middle Aged; Rituximab; Sofosbuvir | 2017 |
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myanmar; Odds Ratio; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2017 |
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Registries; Retrospective Studies; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Immunologic Factors; Prednisolone; Recurrence; Ribavirin; Rituximab; Sofosbuvir; Viral Load | 2017 |
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
Topics: Antiviral Agents; Benzimidazoles; Budgets; Drug Combinations; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Patents as Topic; Public Health; Sofosbuvir; United States; Uridine Monophosphate | 2017 |
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Safety; Sofosbuvir; Treatment Outcome | 2017 |
Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.
Topics: Amides; Antiviral Agents; Catalytic Domain; DNA-Directed RNA Polymerases; Hepacivirus; Hepatitis C; Humans; Mitochondria; Nucleosides; Phosphoric Acids; Sofosbuvir; Structure-Activity Relationship; Substrate Specificity | 2017 |
Belgian experience with direct acting antivirals in people who inject drugs.
Topics: Adult; Aged; Antiviral Agents; Belgium; Carbamates; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2017 |
Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; Kidney Transplantation; Postoperative Complications; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response; Time Factors; Uridine Monophosphate | 2017 |
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2017 |
A not so easy genotype-striking regional differences in SOF/RBV treatment responses in HCV GT2.
Topics: Antiviral Agents; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2017 |
Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Counterfeit Drugs; Drugs, Chinese Herbal; Ephedrine; Fluorenes; Gas Chromatography-Mass Spectrometry; Glycyrrhizic Acid; Hepatitis C; Japan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Sofosbuvir; Tablets; Uridine Monophosphate; Vitamins | 2017 |
Two Antiviral Drugs Approved For Adolescents With HCV.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infant, Newborn; Sofosbuvir; Uridine Monophosphate | 2017 |
Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genetic Diseases, Inborn; Hemorrhage; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2017 |
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Health Services; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Program Development; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Ukraine; Young Adult | 2017 |
Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.
Topics: Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2017 |
Clearance of Hepatitis C Virus Prior to Lung Transplantation: A Case Report.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Lung Transplantation; Male; Middle Aged; Preoperative Care; Sofosbuvir; Uridine Monophosphate | 2017 |
Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver; Liver Transplantation; Male; Middle Aged; Sofosbuvir | 2018 |
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir | 2018 |
Let's Make a Deal: Shortening the Solid Organ Transplant Waiting Time in Exchange for Transmitting and Treating Hepatitis C Infection in the Era of Safe and Effective Directly Acting Antivirals.
Topics: Antiviral Agents; Heart Transplantation; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Waiting Lists | 2018 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus.
Topics: Anti-HIV Agents; Benzimidazoles; Female; Fluorenes; Gastrostomy; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Tablets; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2017 |
New Oral HCV Drug.
Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Benzimidazoles; Drug Therapy; Female; Fluorenes; Hematologic Neoplasms; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir | 2018 |
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication | 2018 |
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load | 2018 |
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Phenotype; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Sofosbuvir | 2018 |
Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hospitals, Urban; Humans; Interferons; Male; Middle Aged; Retrospective Studies; RNA, Viral; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Fluorenes; Hepatitis C; Humans; Male; Sexual Dysfunction, Physiological; Sofosbuvir; Uridine Monophosphate | 2019 |
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome | 2017 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine | 2018 |
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
A preliminary analysis of hepatitis C virus in pancreatic islet cells.
Topics: Antiviral Agents; Cells, Cultured; Cytokines; HEK293 Cells; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Islets of Langerhans; MicroRNAs; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virion; Virus Internalization; Virus Replication | 2017 |
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry; Valine | 2018 |
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine | 2018 |
Sustained improvement of psoriasis associated with HCV after virologic response to sofosbuvir/ribavirin.
Topics: Adolescent; Antiviral Agents; Hepatitis C; Humans; Male; Psoriasis; Ribavirin; Sofosbuvir | 2017 |
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate | 2018 |
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Topics: Aged; Antibodies, Monoclonal, Humanized; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Fluorenes; Hepatitis B; Hepatitis C; Humans; Interferons; Lung Neoplasms; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sofosbuvir | 2018 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2019 |
Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Sequence Deletion; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2018 |
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Phylogeny; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2018 |
Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.
Topics: Antiviral Agents; Benzimidazoles; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Renal Dialysis; Sofosbuvir | 2018 |
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Sofosbuvir; Sustained Virologic Response; Treatment Failure | 2018 |
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2018 |
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2018 |
Drug executives should take a Hippocratic oath.
Topics: Consumer Behavior; Drug Industry; Hepatitis C; Hippocratic Oath; Humans; Patents as Topic; Patient Satisfaction; Sofosbuvir; Trust; Workforce | 2018 |
Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
Topics: Aged; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C; Humans; Kidney; Kidney Diseases; Liver Transplantation; Male; Middle Aged; Recovery of Function; Recurrence; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome | 2019 |
Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cross Infection; Disease Outbreaks; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors | 2018 |
A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
Topics: Acute Disease; Adult; Carbamates; China; Drug Therapy, Combination; Early Diagnosis; Early Medical Intervention; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Tattooing; Valine | 2018 |
Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Portugal; Postoperative Complications; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
Topics: Antiviral Agents; Benzofurans; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Italy; Markov Chains; Quality-Adjusted Life Years; Quinoxalines; Ribavirin; Sofosbuvir | 2018 |
Take a Bow, Pharma, for the Hepatitis C Drugs.
Topics: Antiviral Agents; Benzimidazoles; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate | 2018 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Hepatitis C; Humans; Imidazoles; Incidence; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2018 |
Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retreatment; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2018 |
Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community.
Topics: Africa, Eastern; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Emigrants and Immigrants; Ethnicity; Female; Fluorenes; Genotype; Hepatitis C; Humans; Male; Middle Aged; Middle East; Retrospective Studies; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate | 2019 |
Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Topics: Adult; Antiviral Agents; Carbamates; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; India; Male; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sofosbuvir; Time Factors; Treatment Outcome | 2018 |
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Combinations; Hepacivirus; Hepatitis C; Imidazoles; Lactones; Limit of Detection; Liquid-Liquid Extraction; Male; Models, Animal; Pyrrolidines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Sofosbuvir; Spectrophotometry, Ultraviolet; Sulfones; Ultrasonic Waves; Valine | 2018 |
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Ritonavir; Sofosbuvir; Treatment Outcome | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2018 |
GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Dogs; Drug Combinations; Drug Stability; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Imidazoles; Macrocyclic Compounds; Male; Microsomes, Liver; Mutation; Pyrrolidines; Rats, Sprague-Dawley; Serine Proteases; Serine Proteinase Inhibitors; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2018 |
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Red Cross; Sofosbuvir | 2018 |
Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population.
Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Prevalence; Sofosbuvir; Uridine Monophosphate; Vulnerable Populations | 2018 |
Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis.
Topics: Adenosine Deaminase; Agammaglobulinemia; Antiviral Agents; Benzimidazoles; Fluorenes; Genetic Therapy; Hepatitis C; Humans; Infant; Male; Severe Combined Immunodeficiency; Sofosbuvir; Uridine Monophosphate | 2018 |
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Registries; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recurrence; Sofosbuvir | 2018 |
Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Interactions; Female; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Organ Transplantation; Retrospective Studies; Simeprevir; Sofosbuvir; Sustained Virologic Response; Young Adult | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Health Status Disparities; Hepacivirus; Hepatitis C; Humans; Sofosbuvir | 2018 |
Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Patient Education as Topic; Patient Medication Knowledge; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate | 2018 |
Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma.
Topics: Antiviral Agents; Carbamates; Drug Stability; Fluorescence; Fluorometry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Limit of Detection; Sofosbuvir | 2018 |
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2018 |
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Uridine Monophosphate | 2019 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications.
Topics: Antiviral Agents; ATP-Binding Cassette Transporters; Biological Transport; Female; Guanine; Hepatitis C; Humans; Placenta; Pregnancy; Sofosbuvir; Solute Carrier Proteins; Tenofovir; Trophoblasts | 2018 |
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; RNA; Sofosbuvir | 2018 |
Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Ultrasonography | 2018 |
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; California; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load | 2018 |
Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Living Donors; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2019 |
Hand-foot syndrome due to hepatitis C therapy.
Topics: Antiviral Agents; Hand-Foot Syndrome; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir | 2018 |
Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients.
Topics: Aged; Cardiotoxicity; Chronic Disease; Drug Therapy, Combination; Echocardiography; Female; Heart Function Tests; Hepatitis C; Humans; Longitudinal Studies; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2018 |
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Female; Fluorenes; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Telemedicine; Treatment Outcome; Valine | 2020 |
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Gilead injects own generics into shrinking HCV drug market.
Topics: Antiviral Agents; Benzimidazoles; Biotechnology; Drug Costs; Drug Industry; Drugs, Generic; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate | 2018 |
Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the tr
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir | 2019 |
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir | 2019 |
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine | 2019 |
[Treatment of Hepatitis C: State of the Art 2018].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
Effective drugs on the road to HCV elimination and a therapeutic gap to close.
Topics: Asia; Carbamates; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2019 |
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report.
Topics: Acute Disease; Antiviral Agents; Benzimidazoles; Early Medical Intervention; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Severity of Illness Index; Sofosbuvir; Time Factors; Uridine Monophosphate | 2018 |
Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Humans; Imidazoles; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir | 2019 |
Hepatitis C Virus: No Longer a Barrier to Oncology Care.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasms; Prospective Studies; Sofosbuvir; Sustained Virologic Response | 2019 |
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
Topics: Antiviral Agents; Brazil; Disease Eradication; Drug Costs; Drug Industry; Drugs, Generic; Government Agencies; Hepatitis C; Humans; Legislation, Drug; Patents as Topic; Public Health Practice; Sofosbuvir | 2019 |
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pakistan; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2019 |
Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Proportional Hazards Models; Sofosbuvir; Transplant Recipients; Waiting Lists; Young Adult | 2019 |
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
Topics: Aged; Anemia, Hemolytic; Carnitine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2019 |
Impact of direct-acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients.
Topics: Aged; Antiviral Agents; Disease Management; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Tacrolimus | 2019 |
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2019 |
Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Treatment Outcome | 2019 |
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load | 2019 |
Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4.
Topics: Adolescent; Benzimidazoles; Child; Drug Resistance, Viral; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Phylogeny; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2019 |
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbamates; Drug Interactions; Female; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Safety; Sofosbuvir; Treatment Outcome; Young Adult | 2019 |
Sofosbuvir induced leucocytoclasic vasculitis: a case report.
Topics: Antiviral Agents; Drug Eruptions; Hepatitis C; Humans; Male; Middle Aged; Skin; Sofosbuvir; Vasculitis, Leukocytoclastic, Cutaneous | 2019 |
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Regression Analysis; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Failure | 2019 |
Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Interactions; Female; Fluorenes; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure.
Topics: Acute Disease; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Failure, Acute; Male; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Follow-up Results of
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2019 |
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Failure; Male; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load; Viremia | 2019 |
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Topics: Antiviral Agents; Apolipoprotein A-II; Cell Differentiation; Cholesterol; CRISPR-Cas Systems; Gene Editing; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Hyperlipoproteinemia Type II; Induced Pluripotent Stem Cells; Phenotype; Plasmids; Promoter Regions, Genetic; Proprotein Convertase 9; Receptors, LDL; Sofosbuvir; Sterol Regulatory Element Binding Protein 2 | 2019 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Targeted drugs to tackle hepatitis C.
Topics: Age Factors; Carrier State; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Male; Mass Screening; Middle Aged; Molecular Targeted Therapy; Risk Assessment; Sofosbuvir; Uridine Monophosphate | 2013 |
Trials wrap on interferon-free hepatitis C regimen.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis C; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2013 |
All-oral HCV therapies near approval.
Topics: Administration, Oral; Animals; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Hepatitis Vaccines | 2013 |
Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Topics: Antiviral Agents; Consumer Advocacy; Cost of Illness; Drug Approval; Drugs, Generic; Hepacivirus; Hepatitis C; Humans; Prevalence; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2013 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
FDA approvals usher in the post-interferon era in HCV.
Topics: Drug Approval; Drug Industry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Screening urged for hepatitis C but drug costs are prohibitive.
Topics: Antiviral Agents; Canada; Drug Costs; Hepatitis C; Humans; Mass Screening; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C treatment & management.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate | 2014 |
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Hepatitis C could be virtually eliminated by 2030, experts believe.
Topics: Antiviral Agents; Disease Eradication; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C drugs not reaching poor.
Topics: Anti-HIV Agents; Antiviral Agents; Developing Countries; Drug Costs; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C: Treatment triumphs.
Topics: Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Sovaldi makes blockbuster history, ignites drug pricing unrest.
Topics: Drug Industry; Health Care Costs; Hepatitis C; Income; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
WHO issues guidelines on HCV amid drug cost controversy.
Topics: Antiviral Agents; Drug Costs; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Practice Guidelines as Topic; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; World Health Organization | 2014 |
Elimination on the agenda for hepatitis C.
Topics: Antiviral Agents; Disease Eradication; Global Health; Hepatitis C; Humans; Injections; Interferons; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
Sofosbuvir for the treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
Medicine. Hepatitis C can be cured globally, but at what cost?
Topics: Antiviral Agents; Developing Countries; Drug Costs; Drugs, Generic; Global Health; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Payers consider waiting out budget-busting hepatitis C drug.
Topics: Antiviral Agents; Hepatitis C; Humans; Managed Care Programs; Medicaid; Politics; Product Surveillance, Postmarketing; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genome, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; Recombination, Genetic; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
US health insurers say Gilead hepatitis C drug too costly.
Topics: Antiviral Agents; Health Care Costs; Hepatitis C; Humans; Insurance Carriers; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient.
Topics: Adult; Antiviral Agents; Coinfection; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Sofosbuvir; Treatment Outcome | 2015 |
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
Topics: Amino Acid Substitution; Clinical Trials, Phase III as Topic; Computational Biology; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Sequence Analysis, RNA; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists | 2015 |
The solid-gold wonder drug. A long, difficult and costly research effort gives doctors a new cure for hepatitis C.
Topics: Drug Combinations; Drug Costs; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Guideline: New HCV drugs should go to sickest patients.
Topics: Antiviral Agents; Drug Costs; Hepatitis C; Humans; Patient Selection; Practice Guidelines as Topic; Societies, Medical; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
Topics: Antiviral Agents; Healthcare Disparities; Hepatitis C; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
Mutant Ninja viruses.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious?
Topics: Antiviral Agents; Hepatitis C; Humans; Patient Acceptance of Health Care; Patient Preference; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Sovaldi dilemma likely to get worse.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
The uses and abuses of cost-effectiveness analysis.
Topics: Cost Savings; Cost-Benefit Analysis; Drug Costs; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor.
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; RNA, Viral; Siblings; Sofosbuvir; Tissue Donors; Uridine Monophosphate | 2014 |
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Perspective: incision revision.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Sofosbuvir; Uridine Monophosphate | 2014 |
What is the role of sofosbuvir in treating hepatitis C infection?
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Sofosbuvir | 2015 |
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Fluorescent Antibody Technique; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load; Virus Replication | 2015 |
HIV-hepatitis C co-infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; Internal Medicine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Topics: Aged; Allografts; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Simeprevir; Sofosbuvir | 2015 |
Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
King of the pills.
Topics: Anti-HIV Agents; Chemistry, Organic; Drug Discovery; Hepatitis C; History, 20th Century; History, 21st Century; Sofosbuvir; Uridine Monophosphate | 2015 |
Dare to refuse the exorbitant price of Sovaldi!
Topics: Antiviral Agents; Drug Costs; Drug Industry; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C.
Topics: Antiviral Agents; Biopsy; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C; Humans; Incidence; Lichenoid Eruptions; Male; Middle Aged; Simeprevir; Sofosbuvir | 2015 |
Campaigners challenge patent applications for hepatitis C drug in five countries.
Topics: Antiviral Agents; Argentina; Brazil; China; Drug Costs; Drugs, Generic; Hepatitis C; Humans; Legislation, Drug; Patents as Topic; Russia; Sofosbuvir; Ukraine; Uridine Monophosphate | 2015 |
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
Topics: Aged; Analysis of Variance; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Safety; Reference Values; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list.
Topics: Administration, Oral; Allografts; Antiviral Agents; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Middle Aged; Renal Insufficiency; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Waiting Lists | 2015 |
Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Ribavirin; Simeprevir; Sofosbuvir; Substance Withdrawal Syndrome | 2015 |
A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis C; Hepatorenal Syndrome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Recurrence; Renal Dialysis; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome | 2016 |
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Simeprevir; Sofosbuvir | 2015 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Topics: Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
China rejects patent on hepatitis C drug sofosbuvir.
Topics: Antiviral Agents; China; Cost Control; Drug Costs; Hepatitis C; Humans; Product Surveillance, Postmarketing; Sofosbuvir; Uridine Monophosphate | 2015 |
Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation | 2015 |
Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Male; Postoperative Complications; Simeprevir; Sofosbuvir | 2015 |
Lawsuit seeks access to data from hepatitis C drug trial.
Topics: Access to Information; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fluorenes; Hepatitis C; Humans; Product Surveillance, Postmarketing; Research Design; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2015 |
[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Evidence-Based Medicine; Fluorenes; Gastroenterology; Germany; Hepatitis C; HIV Infections; Humans; Practice Guidelines as Topic; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.
Topics: Antiviral Agents; Cholestasis; Female; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Sofosbuvir | 2015 |
Reply: To PMID 25825070.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Male; Postoperative Complications; Simeprevir; Sofosbuvir | 2015 |
Sofosbuvir (Sovaldi) for hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2015 |
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Standard of Care; Treatment Outcome; Valine | 2016 |
Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
Topics: Antiviral Agents; Female; Graft Survival; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Erythrocytes; Half-Life; Hepatitis C; Hepatocytes; Humans; Monocytes; Nonlinear Dynamics; Phosphates; Phosphorylation; Quality Control; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry | 2015 |
Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir.
Topics: Acute-On-Chronic Liver Failure; Aged; Antiviral Agents; Benzimidazoles; End Stage Liver Disease; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Sofosbuvir | 2015 |
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cross Infection; Disease Outbreaks; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Uridine Monophosphate | 2016 |
Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
Topics: Antiviral Agents; Drug Eruptions; Hepatitis C; Humans; Male; Middle Aged; Pityriasis Rubra Pilaris; Sofosbuvir | 2015 |
Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Contraindications; Drug Interactions; Fluorenes; Hepatitis C; Humans; Nurse Practitioners; Patient Education as Topic; Practice Guidelines as Topic; Sofosbuvir; Uridine Monophosphate | 2015 |
Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Viral Core Proteins; Viral Load | 2016 |
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; North America; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2016 |
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Topics: Aged; Antiviral Agents; Female; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Postoperative Complications; Registries; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
Topics: Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prognosis; Risk Factors; Safety; Sofosbuvir; Viral Load | 2016 |
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Molecular Epidemiology; Sequence Analysis, RNA; Sofosbuvir | 2016 |
Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Medicaid; Middle Aged; New York City; Sofosbuvir; Treatment Outcome; United States | 2015 |
Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate | 2016 |
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2016 |
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2016 |
Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation.
Topics: Antiviral Agents; Biopsy; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
Letter: self-pay behaviour patients with chronic hepatitis C who required direct acting anti-viral urgently in a real-world setting.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir | 2016 |
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2017 |
Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir | 2016 |
Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; New York City; Risk Factors; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Topics: Aged; Antiviral Agents; Biopsy; Canada; Creatinine; Female; Fibrosis; Genotype; Glomerular Filtration Rate; Hepatitis C; Humans; Interferons; Kidney; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir | 2016 |
Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Disease Progression; Hepatitis C; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2016 |
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2016 |
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient.
Topics: Anemia, Aplastic; Benzimidazoles; Female; Fluorenes; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Middle Aged; Myelodysplastic Syndromes; Sofosbuvir; Transplant Recipients; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2016 |
Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Viral Load; Young Adult | 2016 |
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; RNA Viruses; Simeprevir; Sofosbuvir | 2016 |
New Indications for Harvoni.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Approval; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2016 |
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2016 |
Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2016 |
Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients.
Topics: Antiviral Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepatitis C; HIV Infections; Humans; Sofosbuvir | 2016 |
Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.
Topics: Adenosine; Antiviral Agents; Cell Line; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Hepacivirus; Hepatitis C; Humans; Prodrugs; Ribonucleosides; RNA; RNA, Mitochondrial; RNA, Viral; Sofosbuvir; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication | 2016 |
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Health Expenditures; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; Uridine Monophosphate | 2016 |
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
Topics: Antiviral Agents; Compassionate Use Trials; Drug Therapy, Combination; France; Hepacivirus; Hepatitis C; Humans; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Payers Sued Over Coverage Of Expensive Hepatitis C Drugs.
Topics: Drug Combinations; Drug Costs; Hepatitis C; Insurance, Health; Macrocyclic Compounds; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine | 2016 |
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Topics: Asian People; Benzimidazoles; China; Costs and Cost Analysis; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Markov Chains; Models, Economic; Sofosbuvir | 2016 |
Drug Pricing Evolution in Hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Discovery; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin; Ritonavir; Sofosbuvir; Switzerland; United States | 2016 |
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Topics: Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine | 2016 |
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
Topics: Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2016 |
[Not Available].
Topics: AIDS-Related Opportunistic Infections; Benzimidazoles; Cross-Cultural Comparison; Cross-Sectional Studies; Developing Countries; Drug Costs; Europe; Fluorenes; Hepatitis B; Hepatitis C; HIV Infections; Humans; Medical Tourism; Sofosbuvir; United States; Uridine Monophosphate | 2016 |
Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.
Topics: Antiviral Agents; Cell Line, Tumor; Cyclophilins; Cyclosporine; Endoplasmic Reticulum; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Kinetics; Sofosbuvir; Viral Nonstructural Proteins | 2016 |
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Kidney; Middle Aged; Sofosbuvir; Tenofovir | 2016 |
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
Public participation in decision-making on the coverage of new antivirals for hepatitis C.
Topics: Antiviral Agents; Brazil; Community Participation; Decision Making; England; Health Care Rationing; Hepatitis C; Humans; Insurance Coverage; Insurance, Health; Republic of Korea; Sofosbuvir; United States | 2016 |
A pill too hard to swallow: how the NHS is limiting access to high priced drugs.
Topics: Antiviral Agents; Cost Control; Costs and Cost Analysis; Drug Costs; Health Services Accessibility; Hepatitis C; Humans; Legislation, Drug; Sofosbuvir; State Medicine; United Kingdom | 2016 |
Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication | 2016 |
Patents: problem or panacea?
Topics: Drug Costs; Hepatitis C; Humans; Patents as Topic; Pharmaceutical Preparations; Sofosbuvir | 2016 |
Curing HCV infection with 4 weeks-regimen of sofosbuvir and ledipasvir: To be remembered.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Middle Aged; Sofosbuvir | 2016 |
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States | 2016 |
New Drug Treats All Genotypes of Chronic HCV.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; United States; United States Food and Drug Administration | 2016 |
New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; North Carolina; Prisoners; Prisons; Retrospective Studies; Sofosbuvir; State Government; United States; Uridine Monophosphate | 2016 |
Compulsory licences for direct acting antiviral drugs for hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Humans; Italy; Legislation, Drug; Licensure; Sofosbuvir | 2016 |
Questions hang over European patent for hepatitis C drug after ruling.
Topics: Antiviral Agents; Europe; Hepatitis C; Humans; Patents as Topic; Sofosbuvir | 2016 |
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People | 2017 |
Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lymphoma, Follicular; Male; Ribavirin; Sofosbuvir; Viral Load | 2016 |
The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
Topics: Antiviral Agents; Awards and Prizes; Biomedical Research; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Replicon; Sofosbuvir; Virus Replication | 2016 |
HCV-associated cryoglobulinemia vasculitis: are its days numbered?
Topics: Cryoglobulinemia; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Vasculitis | 2017 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Kazakhstan; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Medication Adherence; Proline; Recurrence; Retreatment; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Waiting Lists | 2016 |
Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents.
Topics: Aged; Alcohol Drinking; Alcoholism; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome | 2016 |
Betting on hepatitis C: how financial speculation in drug development influences access to medicines.
Topics: Antiviral Agents; Drug Discovery; Drug Industry; Hepatitis C; Humans; Sofosbuvir | 2016 |
High cost of new drugs.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United Kingdom | 2016 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Dermatologic Agents; Disease Progression; Fluorenes; Hepatitis C; Humans; Male; Psoriasis; Risk Factors; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Ultraviolet Therapy; Uridine Monophosphate | 2017 |
Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
Topics: Antiviral Agents; Coinfection; Hepatitis C; HIV Infections; Humans; Sofosbuvir; T-Lymphocytes; Viremia | 2017 |
Wales approves new hepatitis C drug while England deliberates.
Topics: Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; England; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; State Medicine; Wales | 2016 |
The enigma of value: in search of affordable and accessible health care.
Topics: Budgets; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pharmaceutical; Fees, Pharmaceutical; Health Expenditures; Health Services Accessibility; Hepatitis C; Humans; Sofosbuvir; State Medicine; Switzerland; United Kingdom | 2017 |
Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.
Topics: Administration, Oral; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication.
Topics: Adult; Antiviral Agents; Female; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Ribavirin; Sofosbuvir; Tacrolimus | 2016 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine | 2016 |
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.
Topics: Adult; Allografts; Antibodies, Monoclonal; Antiviral Agents; Basiliximab; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B virus; Hepatitis C; HIV; Humans; Immunosuppression Therapy; Klebsiella pneumoniae; Liver Transplantation; Male; Middle Aged; Nausea; Polymerase Chain Reaction; Pulmonary Disease, Chronic Obstructive; Recombinant Fusion Proteins; RNA, Viral; Simeprevir; Sofosbuvir; Tissue and Organ Procurement; Transplant Recipients; Treatment Outcome | 2017 |
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load | 2017 |
Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.
Topics: Antiviral Agents; Benzimidazoles; Delivery of Health Care, Integrated; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Time Factors | 2017 |
Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
Topics: Amino Acid Substitution; Antiviral Agents; Brazil; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Mutation; Prevalence; Public Health Surveillance; Sofosbuvir; Viral Nonstructural Proteins | 2017 |
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir.
Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Fluorenes; Heart Failure; Heart Transplantation; Hepatic Encephalopathy; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
Topics: Allografts; Antibodies, Monoclonal; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proof of Concept Study; RNA, Viral; Secondary Prevention; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2017 |
Costly Cures.
Topics: Budgets; Hepatitis C; Hepatitis C, Chronic; Humans; Medicaid; Severity of Illness Index; Sofosbuvir; State Government; United States | 2017 |
Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Mutation; Pilot Projects; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.
Topics: Aged; Antiviral Agents; Benzimidazoles; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Odds Ratio; Retrospective Studies; Sofosbuvir; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans | 2017 |
In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Drug Resistance, Viral; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Models, Molecular; Mutation; Phenotype; Protein Conformation; Sofosbuvir; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2017 |
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
Topics: Adult; Antiviral Agents; Developing Countries; Drug Therapy, Combination; Female; Genotype; Health Resources; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pakistan; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglobulinemia; Cytokines; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis Viruses; Humans; Imidazoles; Immune Tolerance; Immunity, Cellular; Male; Middle Aged; Phenotype; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; T-Lymphocyte Subsets; Time Factors; Treatment Outcome; Valine; Vasculitis; Viral Load | 2017 |
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
Topics: Antiviral Agents; B-Lymphocytes; Carbamates; CD4-Positive T-Lymphocytes; Cryoglobulinemia; Cryoglobulins; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Immunoglobulin M; Interleukins; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Pyrrolidines; Receptors, Complement 3d; Receptors, CXCR5; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes, Regulatory; Th17 Cells; Valine; Vasculitis | 2017 |
Synthesis of diastereomerically pure nucleotide phosphoramidates.
Topics: Amides; Amino Acids; Antiviral Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; DNA-Directed RNA Polymerases; Electrons; Esters; Hepacivirus; Hepatitis C; Humans; Magnetic Resonance Spectroscopy; Nucleosides; Nucleotides; Phenols; Phosphoric Acids; Prodrugs; Sofosbuvir; Stereoisomerism; Structure-Activity Relationship; Uridine Monophosphate; Viral Proteins | 2011 |
Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
Topics: Antiviral Agents; Cyclic P-Oxides; Halogenation; Hepacivirus; Hepatitis C; Humans; Isotope Labeling; Nucleosides; Prodrugs; Sofosbuvir; Uridine Monophosphate | 2011 |
Trial watch: an all-oral and interferon-free future for HCV therapy?
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Forecasting; Hepatitis C; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2011 |
Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.
Topics: Amino Acid Sequence; Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Sequence Data; Sequence Alignment; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |